



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/30, 15/62, C07K 14/44, 16/20,</b> <b>A61K 31/70, 38/16, 39/395, A61P 33/02</b>	<b>A1</b>	<b>(11) International Publication Number: WO 00/39298</b>  <b>(43) International Publication Date: 6 July 2000 (06.07.00)</b>
<b>(21) International Application Number:</b> PCT/EP99/10441 <b>(22) International Filing Date:</b> 23 December 1999 (23.12.99)  <b>(30) Priority Data:</b> 60/113,825                      23 December 1998 (23.12.98)    US 2,256,124                      23 December 1998 (23.12.98)    CA  <b>(71) Applicant (for all designated States except US):</b> C.B.F. LETI S.A. [ES/ES]; Sol, 5, Poligono Industrial Norte, E-28760 Tres Cantos (ES).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> BEDATE ALONSO, Carlos [ES/ES]; Pablo Aranda 3, E-28006 Madrid (ES).  <b>(74) Agent:</b> DE BRUIJN, Leendert, C.; Nederlandsch Octrooibu- reau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> CHIMERIC GENE ENCODING THE ANTIGENIC DETERMINANTS OF FOUR PROTEINS OF L. INFANTUM		
<b>(57) Abstract</b>  The present invention relates to a pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis. The pharmaceutical composition contains the protein chimera Q, which is the product of a chimeric gene encoding the antigenic determinants of four proteins of Leishmania infantum.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## CHIMERIC GENE ENCODING THE ANTIGENIC DETERMINANTS OF FOUR PROTEINS OF L. INFANTUM

5

DESCRIPTION**OBJECT OF THE INVENTION**

10           The present specification relates to an application  
for an Invention Patent, regarding a chimeric gene formed  
of the DNA sequences that encode the antigenic  
determinants of four proteins of L. infantum, and to  
15           proteins encoded by said chimeric gene, useful for the  
prevention or treatment of leishmaniosis, in particular  
canine leishmaniosis. The obvious purpose of this lies in  
using the gene sequence or the protein obtained from the  
chimeric gene for providing pharmaceutical compositions  
20           for preventing or treating leishmaniosis, in particular  
canine leishmaniosis, that can be present in the body of a  
patient, for instance as a vaccine or a monoclonal  
antibody preparation. This patient does not have to be a  
dog but can also be a human being who suffers from  
25           diseases that involve immuno-depression. To achieve this,  
a chimeric gene will be produced that encodes a protein  
called PQ consisting of a chimeric product originating  
from an "in vitro" synthesis of a chimeric gene  
constructed "ad hoc", which contains five of the antigenic  
30           determinants of four different proteins. The product is  
configured as highly sensitive and specific for -for  
instance - generating a protective immune responds against  
canine Leishmaniosis, or for preparing antibodies against  
canine Leishmaniosis.

**FIELD OF THE INVENTION**

35           This invention is of utility within the industry  
dedicated to the manufacture of pharmaceutical products in

general.

#### BACKGROUND OF THE INVENTION

The parasitic protozoa of the *Leishmania* genus are the aetiological agents that cause Leishmaniosis, a range  
5 of diseases that have a world-wide distribution and that are characterised in that they give rise to a wide variety of clinical symptoms.

The main forms of Leishmaniosis are zoonotic in nature and humans are considered as secondary hosts.

10 The species denoted *L. Infantum*, widely distributed throughout many Mediterranean areas is the cause of visceral Leishmaniosis (LV) in humans and dogs.

In fact, dogs infected with *L. infantum* are the main animal reserve of this parasite, particularly during the  
15 long incubation period before the clinical symptoms can be observed.

The epidemiological data indicate that there is a direct correlation between the prevalence of canine Leishmaniosis and the transmission of the parasite to  
20 humans. For this reason, it is crucial to detect the disease or infection early on in campaigns undertaken to control the spread of the disease.

The parasite is transmitted to the host vertebrate as a flagellate promastigote, by means of a bite of a fly  
25 of the family "Phlebotominae", and the parasite enter the cells of the mononuclear phages where they differentiate and reproduce as amastigotes, within the phago-lisosomal structure.

The infected cells gather in certain tissues, mainly spleen, liver and lymph nodes. It is estimated that around  
30 15 million people are infected with Leishmaniosis, and every year in the world 500,000 new clinical cases appear in the world, mainly in the underdeveloped and developing world.

35 In the south-western countries of Europe, Visceral Leishmaniosis (VL), is a zoonotic disease caused by the *L.*

Infantum species, as was mentioned earlier. Recent data derived from epidemiological studies indicate that there is an alarming incidence of this infection.

In Italy the reported data for incidence of VL ranges from 14.4% to 37% according to the region.

In Portugal, more particularly in the area around Lisbon, seropositive rates of 8.4% have been found and in the region of the French Maritime Alps different centres of prevalence have been found that vary between 3.2% and 17.1%.

In Spain, the prevalence of Leishmaniosis depends on the zone being studied. In Catalonia an average incidence rate of 9.3% has been observed although in some hot-spots a prevalence of infected dogs of up to 18% has been found.

On the Island of Mallorca, the incidence rate is 14%, and other rates that have been found are: 2.4% in Murcia, 8.8% in Granada, from 10 to 15% in Salamanca, 5.25% in the province of Madrid, and 14% in Caceres.

Although the number of cases of VL in humans caused by *L. infantum* can be considered relatively low, the high percentage of patients with immuno-depression that become infected by *Leishmania* could be related to the high level of this illness in dogs.

In fact, in the South of Europe, 50% of adults that are infected by Leishmaniosis are also patients infected by the HIV virus. On the other hand, according to these data of *Leishmania*-HIV co-infection, it has been estimated that the level of infection (by parasites) can be one or two orders of magnitude higher than this figure due to the existence of a large number of undetected infections.

A common characteristic of the different types of *Leishmania* infection is that it induces a strong humoral response in the host. Therefore, diagnostic methods based on serological techniques are currently the most widely used.

It has been described that these antibodies are

detected even during the asymptomatic phase of the disease in natural and experimental infections.

The sensitivity and specificity of these methods depends on the type, source and purity of the antigen used. In immunological processes that are currently commercialised, complete promastigotes and preparations more or less prepared from these are used as a source of antigen. This method normally leads to cross-reactions with serum from patients suffering from leprosy, tuberculosis, African tripanosomiasis, Chagas disease, malaria and other parasitosis.

The sensitivity and specificity of the serologic methods depend on the type, source and purity of the employed antigen. During the last years a great number of Leishmania antigens have been characterised, some of them can be considered as proteins specific to the parasite.

Among these proteins specific to the parasite, the surface protease GP63, the surface glycoprotein gp46 and the lipophosphoglicane associated KMP-11 protein deserve a mention.

An additional group of Leishmania antigens are formed of evolutionarily conserved proteins, such as kinesine, thermally induced proteins, actin and tubulin.

As part of a strategy to develop a specific serological diagnostic system for Leishmaniosis canine, a laboratory based project has been undertaken to identify the antigens of *L. infantum*, by means of an immunodetection search of an expression library for genes of *L. infantum* using dog serum with active visceral Leishmaniosis.

It has been observed that most of the antigens isolated by this method belong to the family of proteins conserved during the course of evolution. The identification of the B epitopes of these antigens indicate, however, that in all cases the antigenic determinants were localised in regions that were not well

conserved.

In particular, the acidic ribosomal proteins LiP2a and LiP2b are recognised by more than 80% of the VL sera.

It has been confirmed that these proteins contain  
5 disease specific antigenic determinants, and that the recombinant proteins LiP2a and LiP2b, from which a fragment had been removed, could be used as a specific instrument able to distinguish between VL and Chagas disease.

10 It has also been shown that the PO ribosomal protein of *L. infantum*, very highly conserved on the evolutionary scale, is recognised by a high percentage of VL dog sera.

Furthermore, the antigenic determinants are found  
15 exclusively on the C-terminus of the protein, that is to say, in the region that has been poorly conserved during the course of evolution.

It has been observed that in 78% of the VL dog sera, antibodies against H2A protein are also present, and it  
20 has been confirmed that despite the sequence identity in all the H2A proteins among eukaryotic organisms, the humoral response to this protein in VL sera is particularly provoked by determinants specific to the *Leishmania* protein H2A.

The antigenic determinants recognised by the VL dog  
25 sera are found at both termini of the H2A protein.

The obvious solution to the problem currently encountered in this art would be to have an invention that would allow the assembly of a synthetic chimeric gene that contained the DNA regions encoding the antigenic  
30 determinants specific to the proteins LiP2a, LiP2b, LiPO, and H2A, with a view to constructing a protein rich in antigenic determinants.

However, as far as the applicant is aware, there is currently no invention that contains the characteristics  
35 described as ideal, with a view to reaching the desired aim. This aim is the construction of a protein rich in

antigenic determinants, arising from the assembly of a chimeric synthetic gene, that contains the DNA regions encoding the antigenic determinants specific to the aforementioned proteins.

5 **DESCRIPTION OF THE INVENTION**

In a first aspect, the invention relates to a chimeric gene formed by the DNA sequences that encode antigenic determinants of four proteins of *L.infantum*, useful for preventing or treating canine Leishmaniosis.

10 In a further aspect, the invention relates to a protein encoded by said chimeric gene, containing one or more of the antigenic determinants of four proteins of *L.infantum* encoded by the chimeric gene.

15 The invention further relates to method for preventing and/or treating canine Leishmaniosis in a human being or an animal. In this therapeutic method, the chimeric gene of the invention or the protein encoded by it can be used. Also, antibodies against the protein encoded by the chimeric gene of the invention, or a  
20 antigenic part thereof such as an epitope, can be used.

In further aspects, the invention relates to pharmaceutical compositions for the prevention and/or treatment, in humans and/or animals, of Leishmaniosis, comprising an active substance derived from or directed  
25 against the chimeric gene of the invention and/or the protein encoded by it, or parts thereof. The active substance is preferably such that it can be used in a pharmaceutical composition for the treatment and/or prevention of Leishmaniosis.

30 In particular, the pharmaceutical composition will be in a form of a vaccin, containing the protein encoded by the chimeric gene of the invention, or one or more parts thereof, containing one or more of the antigenic determinants of the protein encoded by the chimeric gene  
35 of the invention.



Thus, in a further aspect, the invention relates to a pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis, formed:

- 5 a) by the protein Chimera Q, or a variant of this protein containing modifications or substitutions of preserved amino acids administered to a subject (human or animal), or
- 10 b) by protein Q in isolated form or combined with any physiological adjuvant by the intraperitoneal, subcutaneous or intramuscular route.

The invention also relates to a vaccine that is able to stimulate the production of antibodies that recognize the Leishmania parasite, formed

- 15 a) by the protein Chimera Q or a variant of this protein that differs from protein Q in preserved amino acids, administered to a subject (human or animal), or
- b) by protein Q in isolated form or combined with a physiological adjuvant by the intraperitoneal, subcutaneous or intramuscular route.

- 20 Furthermore, the invention relates to a pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis formed
- a) by protein Q, or a variant of this protein containing modifications or substitutions of preserved amino
- 25 acids, combined with the protein LiHsp70, complete or fragmented, administered to a subject (human or animal), or
- b) by protein Q in isolated form or combined with a physiological adjuvant by the intraperitoneal,
- 30 subcutaneous or intramuscular route.

In yet another aspect, the invention relates to a pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis, formed

- 35 a) by any DNA vector bearing the sequence that codes for the protein Chimera Q, or a variant of that sequence that contains modifications or substitutions of

nucleotides that code for preserved amino acids,  
administered to a subject (human or animal), or  
b) by a DNA vector that contains protein Q combined with  
a physiological adjuvant, administered by the  
5 intraperitoneal, intramuscular or subcutaneous route.

Another aspect of the invention relates to a  
pharmaceutical composition for the prevention and  
treatment, human or animal, of leishmaniasis, formed  
a) by any DNA vector bearing:

- 10 1) the sequence that codes for the protein Chimera  
Q, or a variant of that sequence that contains  
modifications or substitutions of nucleotides  
that code for preserved amino acids, and
- 2) the sequence of nucleotides that codes for the  
15 protein LiHsp70 or variants thereof that differs  
with respect to preserved amino acids,  
administered to a subject (human or animal), or  
b) by any vector that contains the DNA sequence that  
codes for protein Q as defined under a) administered  
20 with a physiological adjuvant by the intraperitoneal,  
intramuscular or subcutaneous route.

In a further embodiment, the pharmaceutical  
composition of the invention comprises antibodies directed  
to the protein encoded by the chimeric gene of the  
25 invention, or parts thereof.

The pharmaceutical preparations of the invention may  
further contain all known adjuvants, solvents, buffers  
etc. known per se for pharmaceutical compositions and/or  
vaccines.

30 In a further aspect, the invention relates to a  
method for the treatment or prevention of Leishmaniosis,  
using a pharmaceutical composition or a vaccin according  
to the invention, or a preparation comprising antibodies  
directed against the protein encoded by the chimeric gene  
35 of the invention.

This method will generally comprise administering an

active substance directed against the chimeric gene or the protein to a human being or animal, such as a dog, in a pharmaceutically active amount.

For the prevention of Leishmaniasis, a vaccin  
5 comprising the protein encoded by the chimeric gene, or encoding one or more parts of said protein comprising one or more of the antigenic determinants, will be administered to a human being to elicit a protective immune response.

Administration of the preparations, antibodies  
10 and/or vaccins of the invention may be carried out in a manner known per se, such as orally, intramuscularly, intravenously, subcutaneously, by (drip)infusion etc.. Preferably, the preparation or a vaccin is injected, whereas with an antibody preparation, an infusion can be  
15 used.

It should be noted that when herein, reference is made to the chimeric gene of the invention, this term also encompasses nucleic acid sequences that can hybridize with the sequence mentioned below under moderate or stringent  
20 hybridizing conditions.

In this context, heterologous hybridisation conditions can be as follows: hybridisation in 6 x SSC (20xSSC per 1000 ml : 175.3 g NaCl, 107.1 g sodium citrate.5H<sub>2</sub>O, pH 7.0), 0.1% SDS, 0.05% sodium  
25 pyrophosphate, 5\* Denhardt's solution (100 x Denhardt's solution per 500 ml : 10 g Ficoll-400, 10 g polyvinylpyrrolidone, 10 g Bovine Serum Albumin (Pentax Fraction V)) and 20 µg/ml denatured herring sperm DNA at 56°C for 18-24 hrs followed by two 30 min. washes in 5 x SSC, 0.1 %  
30 SDS at 56°C and two 30 min. washes in 2 x SSC, 0.1% SDS at 56°C.

For instance, sequences that can hybridize with the sequence mentioned below include mutant DNA sequences which encode proteins with the same biological function as  
35 the protein encoded by the sequence mentioned hereinbelow. Such mutant sequences can comprise one or more nucleotide

deletions, substitutions and/or additions to the sequence mentioned below. Preferably, the mutant sequences still have at least 50%, more preferably at least 70%, even more preferably more than 90 % nucleotide homology with the sequence given hereinbelow.

The term chimeric gene as used herein also encompasses nucleic acid sequences that comprise one or more parts of the sequence mentioned hereinbelow. Preferably, such sequences comprise at least 10%, more preferably at least 30%, more preferably at least 50% of the nucleotide sequence given hereinbelow. Such sequences may comprise a contiguous fragment of the sequence mentioned hereinbelow, or two or more fragments of the sequence given below that have been combined in and/or incorporated into a single DNA sequence.

It should be noted that when herein, reference is made to a protein encoded by the chimeric gene of the invention, this term also includes mutant proteins that still essentially have the same biological function. Such mutant proteins can comprise one or more amino acid deletions, substitutions and/or additions compared to the protein encoded by the sequence mentioned below. Preferably, the mutant proteins still have at least 50%, more preferably at least 70%, even more preferably more than 90 % amino acid homology with the sequence given hereinbelow.

The term protein also encompasses fragments of the protein encoded by the chimeric gene of the invention. Such fragments preferably still show the biological activity of the full protein. Preferably, such proteins comprise at least 30%, more preferably at least 50% of the amino acid sequence of the full protein. Also, two or more fragments of the full protein encoded by the chimeric gene of the invention may be combined to form a single protein.

More specifically, the invention relates to a chimeric gene formed by the DNA sequences that encode

antigenic determinants of four proteins of *L. infantum*, encoding a protein useful for pharmacological purposes, in particular for the prevention and/or treatment of Leishmaniosis, in particular canine Leishmaniosis, and obtaining the final product or the construction of the chimeric gene that encodes a polypeptide that contains all the selected antigenic determinants, characterised in that it uses a cloning strategy in which the clone that expresses the protein rLiPO-Ct-Q is used as an initial vector, and to this vector, by means of the use of suitable restriction sites, fragments of DNA are sequentially added that encode the proteins LiP2a-Q, LiP2b-Q, LiH2A-Ct-Q, LiH2A-Nt-Q, and after each step of cloning the correct orientation of each one of the inserts is deduced and the size of the expression products, the complete deduced sequence of amino acids of the final fusion protein, pPQV, expressed in the pMal vector is:

```

MBP  IEGRPLTPRSAKKAVRKSGSKSAKCGLIFPVGRVGGMMRRGYARRIGA 50
20  SGAPRISEFSVKAAAQSGKKRCRLNPRTVMLAARHDDDIGTLLKNVTLSHSGVV 140
    PNISKAMAKKKGGKKGKATPSAPEFGDSSRPMSTKYLAAYALASLSKASPSQAD 157
    VEAICKAVHIDVDQATLAFVMESVTGRDVATLIAEGAAKMSAMPAASSGAAAGV 211
    TASAAGDAAPAAAAAKKDEPEEEADDDMGPSVRDPMQYLAAYALVALSGKTPSK 265
    STAGAGAGAVAEAKKEEPEEEADDDMGPDLPAAAAAPAAPSAAAKAAPEESD 374
25  EDDFGMGGLF (SEQ ID NO.3)

```

The invention also relates to a pharmaceutical composition for the prevention and treatment, in humans or animals, of Leishmaniasis formed :

30 a- by the protein Chimera Q, or a variant of this protein which contains modifications or substitutions of conserved amino acids, administered to a subject (human or animal), either

35 b- in isolated form or together with any physiological adjuvant via the intraperitoneal, subcutaneous or intramuscular routes.

Also, the invention relates to a vaccine capable of stimulating the production of antibodies which recognise the Leishmania parasite, formed

a- by the protein Chimera Q or a variant of this protein which differs from protein Q in conserved amino acids administered to a subject (human or animal), either

b- in isolated form or together with any physiological adjuvant via the intraperitoneal, subcutaneous or intramuscular routes.

Another aspect of the invention comprises a pharmaceutical composition for the prevention and treatment, in humans or animals, of Leishmaniasis formed :

a- by protein Q, or a variant of this protein which contains modifications or substitutions of conserved amino acids, bound to protein LiHsp70, complete or fragmented, administered to a subject (human or animal), either

b- in isolated form or together with any physiological adjuvant via the intraperitoneal, subcutaneous or intramuscular routes.

A further pharmaceutical composition of the invention for the prevention and treatment, in humans or animals, of Leishmaniasis can be formed:

a- by any DNA vector carrying the sequence which encodes the protein Chimera Q, or a variant of this sequence which contains modifications or substitutions of nucleotides which code for conserved amino acids, administered to a subject (human or animal), either

b- by the intramuscular or subcutaneous routes.

In yet another aspect, the invention relates to a pharmaceutical composition for the prevention and treatment, in humans or animals, of Leishmaniasis formed :

a- by any DNA vector carrying 1- the sequence which encodes the protein Chimera Q, or a variant of this sequence which contains modifications or substitutions of nucleotides which code for conserved amino acids, and 2 - the sequence which encodes the protein LiHsp70, or

variants of the same which differ in conserved amino acids, administered to a subject (human or animal), either

b- by the intramuscular, subcutaneous or intramuscular route.

The invention also relates to a nucleotide sequence and to a protein useful for pharmacological purposes, in particular for the prevention and/or treatment of Leishmaniosis, in particular canine Leishmaniosis, having the DNA and amino acid sequence as shown below expressed in the vector PQ31. The aminoacid sequence contains a fragment from the vector (AA 1-37). The rest of the aminoacid sequence is identical to that of SEQ ID NO 3 except in the MBP moiety and the first seven aminoacids (AA 1-7):

1	ATG AGA GGA TCT CAC CAC CAC CAC CAC CAC ACG GAT CCG CAT GCG	45
	Met Arg Gly Ser His His His His His His Thr Asp Pro His Ala	
		5 10 15
46	AGC TCG AAC AAC AAC AAC AAT AAC AAT AAC AAC AAC CTC GGG ATC	90
	Ser Ser Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Gly Ile	
		20 25 30
91	GAG GGA AGG CCT TTA GCT ACT CCT CGC AGC GCC AAG AAG GCC GTC	135
	Glu Gly Arg Pro Leu Ala Thr Pro Arg Ser Ala Lys Lys Ala Val	
		35 40 45
136	CGC AAG AGC GGC TCC AAG TCC GCG AAA TGT GGT CTG ATC TTC CCG	180
	Arg Lys Ser Gly Ser Lys Ser Ala Lys Cys Gly Leu Ile Phe Pro	
		50 55 60
181	GTG GGC CGC GTC GGC GGG ATG ATG CGC CGC GGC CAG TAC GCT CGC	225
	Val Gly Arg Val Gly Gly Met Met Arg Arg Gly Gln Tyr Ala Arg	
		65 70 75
226	CGC ATC GGT GCC TCT GGC GCC CCC AGG ATT TCA GAA TTC TCC GTG	270
	Arg Ile Gly Ala Ser Gly Ala Pro Arg Ile Ser Glu Phe Ser Val	
		80 85 90
271	AAG GCG GCC GCG CAG AGC GGG AAG AAG CGG TGC CGC CTG AAC CCG	315
	Lys Ala Ala Ala Gln Ser Gly Lys Lys Arg Cys Arg Leu Asn Pro	

				95					100					105	
				316										360	
5				CGC	ACC	GTG	ATG	CTG	GCC	GCG	CGC	CAC	GAC	GAC	ACG
				Arg	Thr	Val	Met	Leu	Ala	Ala	Arg	His	Asp	Asp	Thr
								110					115		120
				361										405	
10				CTT	CTG	AAG	AAC	GTG	ACC	TTG	TCT	CAC	AGC	GGC	AAC
				Leu	Leu	Lys	Asn	Val	Thr	Leu	Ser	His	Ser	Gly	Asn
								125					130		135
				406										450	
15				ATC	AGC	AAG	GCG	ATG	GCA	AAG	AAG	AAG	GGC	GGC	AAG
				Ile	Ser	Lys	Ala	Met	Ala	Lys	Lys	Lys	Gly	Gly	Lys
								140					145		150
				391										495	
20				GCG	ACA	CCG	AGC	GCG	CCC	GAA	TTC	GGA	TCC	TCT	TCC
				Ala	Thr	Pro	Ser	Ala	Pro	Glu	Phe	Gly	Ser	Ser	Ser
								155					160		165
				496										540	
25				ACC	AAG	TAC	CTC	GCC	GCG	TAC	GCT	CTG	GCC	TCC	GCG
				Thr	Lys	Tyr	Leu	Ala	Ala	Tyr	Ala	Leu	Ala	Ser	Ala
								170					175		180
				541										585	
30				TCC	CCG	TCT	CAG	GCG	GAC	GTG	GAG	GCT	ATC	TGC	CAC
				Ser	Pro	Ser	Gln	Ala	Asp	Val	Glu	Ala	Ile	Cys	His
								185					190		195
				596										630	
35				ATC	GAC	GTC	GAC	CAG	GCC	ACC	CTC	GCC	TTT	GTG	GTT
				Ile	Asp	Val	Asp	Gln	Ala	Thr	Leu	Ala	Phe	Val	Val
								200					205		210
				641										675	
40				ACG	GGA	CGC	GAC	GTG	GCC	ACC	CTG	ATC	GCG	GAG	AAG
				Thr	Gly	Arg	Asp	Val	Ala	Thr	Leu	Ile	Ala	Glu	Lys
								215					220		225
				676										720	
45				ATG	AGC	GCG	ATG	CCG	GCG	GCC	AGC	TCT	GGT	GCC	GTC
				Met	Ser	Ala	Met	Pro	Ala	Ala	Ser	Ser	Gly	Ala	Val
								230					235		240
				721										765	
50				ACT	GCT	TCC	GCT	GCG	GGT	GAT	GCG	GCT	CCG	GCT	GCG
				Gly	Asp	Ala	Ala	Pro	Ala	Ala	Ala	Ala	Ala	Lys	Pro
								245					250		255
				766										810	
55				AAG	AAG	GAC	GAG	CCC	GAG	GAG	GAG	GCC	GAC	GAC	CCC
				Thr	Ala	Ser	Ala	Ala	Glu	Glu	Glu	Ala	Asp	Asp	Pro
								260					265		270



5	811	TCT AGA GTC GAC CCC ATG CAG TAC CTC GCC GCG TAC GCC CTC	855
	Ser Arg Val Asp Pro Met Gln Tyr Leu Ala Ala Tyr Ala Leu	Val	
		275 280	285
10	856	GCG CTG TCT GGC AAG ACG CCG TCG AAG GCG GAC GTT CAG GCT	900
	Ala Leu Ser Gly Lys Thr Pro Ser Lys Ala ASP Val Gln Ala	Val	
		290 295	300
15	901	CTG AAG GCC GCC GGC GTT GCC GTG GAT GCC TCC CGC GTG GAT	945
	Leu Lys Ala Ala Gly Val Ala Val Asp Ala Ser Arg Val Asp	Ala	
		305 315	315
20	946	GTC TTC CAG GAG GTG GAG GGC AAG AGC TTC GAT GCG CTG GTG	990
	Val Phe Gln Glu Val Glu Gly Lys Ser Phe Asp Ala Leu Val	Ala	
		320 325	330
25	991	GAG GGC CGC ACG AAG CTG GTG GGC TCT GGC TCT GCC GCT CCT	1035
	Glu Gly Arg Thr Lys Leu Val Gly Ser Gly Ser Ala Ala Pro	GCT	
		335 340	345
30	1036	GGC GCT GTC TCC ACT GCT GGT GCC GGC GCT GGC GCG GTG GCC	1080
	Gly Ala Val Ser Thr Ala Gly Ala Gly Ala Gly Ala Val Ala	GAG	
		350 355	360
35	1081	GCG AAG AAG GAG GAG CCC GAG GAG GAG GAG GCC GAT GAT GAC	1125
	Ala Lys Lys Glu Glu Pro Glu Glu Glu Glu Ala Asp Asp Asp	ATG	
		365 370	375
40	1136	GGC CCC GTC GAC CTG CAG CCC GCC GCT GCC GCG CCG GCC GCC	1170
	Gly Pro Val Asp Leu Gln Pro Ala Ala Ala Ala Pro Ala Ala	CCT	
		380 385	390
45	1171	AGC GCC GCT GCC AAG GAG GAG CCG GAG GAG AGC GAC GAG GAC	1215
	Ser Ala Ala Ala Lys Glu Glu Pro Glu Glu Ser Asp Glu Asp	GAC	
		395 400	405
50	TTC GGC ATG GGC GGT CTC TTC TAAGCGACTC GCCATCTCTT		1256
	Phe Gly Met Gly Gly Leu Phe		
		410 412	
55	1257	AGCCTCCTTG TGGTGCGCTT GAGGTGCTCT CGCTCTGCTT CTCCTTG CAG	1306
	1307	TGTTGGCTGA CTCTGGCGGG TATGTGCCGT CGCATTACAC CCACCTCTCC	1356
	1357	CACCCCTTTG CCCTACGCGC TCGCATGCGC AATCCGTGAA TCATCGAGGG	1406

1407

AAGTCTCTCT GGGTGGCAGT GGGTAAGCTT 1436

(SEQ ID NO.1 and SEQ ID NO.2)

or a mutant or fragment thereof that can be used for generating a protective immune response in a human or animal against Leishmaniosis, and to a pharmaceutical composition for the prevention and treatment, in humans or animals, of Leishmaniasis, comprising this protein or a mutant or fragment thereof that can be used for generating a protective immune response in a human or animal against Leishmaniosis. This protein is derived from the insertion of gene PQV in the expression vector pQE31. Here said chimeric gene preferably encodes a polypeptide generated with a molecular weight of 38 kD and an isoelectric point of 7.37.

Also, the invention relates to a vaccine capable of stimulating the production of antibodies which recognise the Leishmania parasite, comprising the protein mentioned above or a mutant or fragment thereof that can be used for generating a protective immune response in a human or animal against Leishmaniosis.

A further aspect of the invention encompasses a pharmaceutical composition for the prevention and treatment, in humans or animals, of Leishmaniasis, comprising antibodies directed against the protein mentioned above or a mutant or fragment thereof, preferably containing one or more antigenic determinants such as an epitope.

The invention further relates to a method for the prevention or treatment of Leishmaniosis in a human or animal, comprising administering to the human or animal a pharmaceutical composition as described above, or to a method for preventing Leishmaniosis in a human or animal, comprising administering to the human or animal a vaccine as described above.

The chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of *L. infantum* and protein obtained, useful for preventing and/or treating Leishmaniosis, that the invention proposes, in its own right constitutes an obvious novelty within its field of application, as according to the invention, a synthetic chimeric gene is produced that as it is obtained by assembly, containing the DNA region encoding the antigenic determinants specific to the proteins LiP2a, LiP2b, LiPO and H2A, thus constructing a protein rich in antigenic determinants. The chimeric gene obtained is expressed in *Escherichia coli* and the product has been analysed with respect to its antigenic properties. The results confirm that this chimeric protein maintains all the antigenic determinants of the parent proteins and that it constitutes a relevant pharmaceutically useful element for canine VL, with a sensibility that oscillates between 80% to 93%, and a specificity of between 96% to 100%.

More particularly, the chimeric gene formed by the DNA sequences that encode the antigenic determinants of four proteins of *L. infantum* and the protein encoded by it, useful for the prevention and/or treatment of canine Leishmaniosis and protein obtained object of the invention, is produced by means of the following stages, namely:

- Construction of the chimeric gene. Methodology.  
Cloning strategy.

- Cloning of DNA sequences that encode antigenic determinants of the histone protein H2A.

- Cloning of the sequences that encode rLiP2a-Q and rLiP2b-Q.

- Cloning of the sequence rLiPO-Q.

- Cloning of the chimeric gene.

- Construction of the chimeric gene from the construction of intermediate products.

Cloning of epitopes specific to the *L. infantum* antigens.

- Construction of the final product

5 Construction of the chimeric gene that encodes a polypeptide that contains all the selected antigenic determinants.

- optionally expression of the sequence thus obtained.

- Evaluation of the final product.

Sera.

10 Purification of proteins

Electrophoresis of proteins and immuno-analysis.

Measurements by Fast-ELISA

- Evaluation of the final product.

Antigenic properties.

15 Sensitivity and specificity of the chimeric protein CP in the serum diagnosis of canine VL.

The strategy followed by the cloning of DNA sequences that encode each one of the selected antigenic determinants is the same in all cases, and in a first  
20 step, the sequence of interest is amplified by means of a PCR and the use of specific oligonucleotides that contain targets for restriction enzymes at the extremes.

For the cloning step, the amplified product is directed by means of the appropriate restriction enzyme  
25 and it is inserted in the corresponding restriction site of the plasmid pUC18.

After sequencing the DNA, the insert is recovered and sub-cloned to the corresponding restriction site of the modified plasmid denominated pMAL-c2. The modification  
30 is made by inserting a termination codon downstream of the target HindIII in the polylinker of pMal-c2, denominating the resulting plasmid pMAL-c2\*.

Regarding the cloning of the DNA sequence that encodes the antigenic determinants of the histone protein  
35 H2A, it should be pointed out that the cDNA of the clone cL71, that encodes the histone H2A of *L. infantum*, is used

as a template for the PCR reactions, and for the DNA amplification, that encodes the N-terminal region of the histone H2A, more exactly rLiH2A-Nt-Q, the following oligonucleotides are used: sense 5'-  
5 **CCTTTAGCTACTCCTCGCAGCGCCAAG**-3' (position 84-104 of the sequence cL71); antisense 5'**CCTGGGGCGCCAGAGGCACCGATGCG**-3' (inverse and complimentary to position 204-224 of the sequence cL71).

10 The sequences that are included in the oligonucleotides for the cloning and that are not present in the parent sequence cL-71 are marked in boldface type.

The amplified DNA fragment is cloned directly from the restriction site XmnI of pMAI-c2\*.

15 The fragment is sequenced by means of the initiator #1234 ma1E and the antigenic C-terminal region of histone H2A, in particular rLiH2A-Ct-Q, is amplified with the following oligonucleotides. These are:

Sense, 5'-GAATTCTCCGTAAGGCGGCCGCGCAG-3' (position 276-296 of the sequence cL71).

20 Antisense, 5'-GAATTCGGGCGCGCTCGGTGTCGCCTTGCC-3' (inverse and complimentary to the positions 456-476 of the plasmid cL71).

25 A triplet that encodes proline (indicated as GGG after the underlined letters) is included in the anti-sense oligonucleotide, the restriction site EccRI that is included in both oligonucleotides for cloning is indicated by underlining.

30 Regarding the cloning of the sequences that encode rLiP2a-Q, it should be pointed out that the regions of interest are amplified by PCR from cDNAs encoding LiP2a and LiP2b.

The oligonucleotides that are used for constructing the expression clone LiP2a-Q, are the following.

Sense, 5'-GTCGACCCCATGCAGTACCTCGCCGCGTAC-3'.

35 Anti-sense, 5'-GTCGACGGGGCCCATGTCATCATCGGCCTC-3'.

It should be pointed out that the SalI restriction

sites added to the 5' extremes of the oligonucleotides have been underlined.

When constructing the expression clone LiP2b-Q, the oligonucleotides used were:

5        Sense, 5'-TCTAGACCCGCCATGTCGTCGTCTTCCTCGCC-3'.

      Anti-sense, TCTAGAGGGGCCATGTCGTCGTCTCGGCCTC-3'.

      At the 5'extremes of the oligonucleotides the restrictions sites are included for the enzyme XbaI (underlined), and due to the cloning needs, an additional  
10       triplet, encoding a proline residue, is included downstream of the restriction site.

      Regarding the cloning of the sequence rLiPO-Q, it should be pointed out that the cloning of the DNA sequence of the C-terminal region of the protein PO of *L. infantum*  
15       is carried out by amplifying a clone of cDNA called L27 and the following oligonucleotides:

      Sense, 5'-CTGCAGCCCGCCGCTGCCGCGCCGGCCGCC-3' (positions  
1-24 of the L27 cDNA) and the initiator of the pUC18 sequence (#1211), the amplified DNA is directed by the  
20       enzymes PstI+HindIII, with later insertion into the plasmid pMAL-c2.

      The resulting clone is denominated pPQI and it should be noted that the restriction site PstI is included in the nucleotide with sense (underlined sequence) and that the  
25       restriction target HindIII is present in the cDNA L27.

      Regarding the cloning of the chimeric gene, it should be pointed out that the DNA sequences that encode the five antigenic determinants are assembled into a chimeric gene, and this assembly is carried out on the clone pPQI, to  
30       which the codifying regions for the antigenic regions LiP2a-Q are added sequentially in the 3' direction (naming the results of cloning pPQII), LiP2b-Q (clone pPQIII), LiH2a-Ct-Q (clone pPQIV) and LiH2A-Nt-Q (clone pPQV).

      Finally, the insert obtained after the SacI+HindIII  
35       digestion of the final clone pPQV is inserted into the pQE31 expression plasmid, naming the resulting clone pPQ.

**DESCRIPTION OF THE DRAWINGS**

To complete the description that is being made and with the aim of aiding the understanding of the characteristics of the invention, the present disclosure is accompanied, as an integral part thereof, by a set of plans of illustrative nature that are not limiting. The following is represented:

Fig 1. Corresponds to the expression (A), purification in amylose columns (B) and the antigenicity (C: Western blot; D: ELISA) of each one of the recombinant proteins fused to the maltose binding protein. The figure under D also presents the reactivity in ELISA of each one of the recombinant protein relative to the complete protein.

Fig 2. Graphic representation of the different vectors considered to obtain the chimeric gene object of the invention, from which the pertinent protein destined to carry out an accurate diagnostic on animals or human beings that show symptoms of Leishmaniosis will be extracted.

Fig 3. Corresponds to the identification of the protein obtained from the chimeric gene fused to the MBP protein, the preparation of which is represented in Figure 2.

Fig 4. Corresponds to the expression (A), purification in amylose columns (B) and the antigenicity (C: Western blot; F: ELISA) of the intermediates and of the final chimeric protein fused to the maltose binding protein(PQI-PGV). The figure also represents the expression of the chimeric protein (D lane 1), purification in Ni-Nt agarose columns (D lane 2) and the antigenicity of the purified protein against a VL serum (E: Western blot) and against a collection of sera (F: PQ in ELISA).

Fig 5. Shows finally a synthesised graphical representation of the reactivity of a wide variety of

canine sera, divided into three groups. The first group contain animals with real infection by *L. infantum*. The second group includes serum obtained from dogs with various clinical symptoms but that are not infected with *Leishmania*, and a third group is made up of fifteen control sera from healthy dogs. This figure demonstrates the value of the invention for carrying out serological diagnosis of VL.

#### **PREFERRED EMBODIMENT OF THE INVENTION**

The chimeric gene formed from the DNA sequences that encode the antigenic determinants of four proteins of *L. infantum*, useful for the serological diagnosis of canine Leishmaniosis and the protein obtained that is being proposed are constituted from the construction of intermediate products. In a first instance, cloning of epitopes specific to the antigens of *L. infantum* is carried out, which is configured on the basis of earlier studies on the antigenic properties of four protein antigens of *L. infantum* (LiP2a, PiPO, LiP2b, LiH2a), which allow the existence of B epitopes to be defined for these proteins, and which are specifically recognised by the canine sera of VL.

With a view to improving the antigenic specificity of these antigens with respect to the proteins of *L. infantum*, the specific antigenic determinants are cloned from these proteins. After deleting certain regions of these proteins these can be recognised by sera from animals that are carriers of VL and other different diseases.

By using the specific oligonucleotides and amplification by PCR of regions specific to the genes LiP2a, LiP2b, PO and H2A, several clones are constructed that express the recombinant proteins rLiPO-Ct-Q, rLiP2a-Q, rLiP2b-Q, rLiH2A-Ct-Q and rLiH2A-Nt-Q, just has been detailed in the description of the invention relating to



the methodology, where the cloning details are described.

The recombinant proteins used are the following:

- rLiPO-Ct-Q, which corresponds to the 30 C-terminal residues of the ribosomal protein LiPO.

- rLiP2a-Q and rLiP2b-Q, that are derived from the ribosomal proteins LiP2a and LiP2b respectively.

- Two sub-regions of the histone H2A, that correspond to the 46 N-terminus residues (xLiH2A-Nt-Q), and to the 67 C-terminus residues (residues (xLiH2A-Ct-Q)).

Each one of the recombinant proteins fused to the maltose binding protein (MBP) is expressed in *E. Coli*, as represented in Figure number 1A, and they were purified by affinity chromatography on a amylose column B. After the process of purification electrophoresis was carried out on the recombinant proteins (lanes 1 to 5).

With the aim of analysing whether the recombinant proteins were recognised by VL canine sera, a Western blot was incubated, containing the recombinant proteins in a mixture of three VL canine sera. Given that all these proteins are recognised by the sera, it is concluded that the antigenic determinants present in the parent proteins are maintained in the recombinant proteins (C).

The antigenic properties of the recombinant proteins are compared with the antigenic determinants of the parent antigens by means of a FAST ELISA, testing against a collection of 26 VL canine sera, just as is shown in the section of Figure number 1D, and the fact that the sera showed a similar reactivity value, both against the selected antigenic regions and the corresponding complete proteins, demonstrates that no alteration to the antigenic epitope has occurred during the cloning procedure.

In regard to the construction of the final product, more exactly of the chimeric gene that encodes a polypeptide that contains all the selected antigenic determinants, it should be pointed out that the cloning strategy is indicated following Figure number 2 section A.

The intermediate products generated during the process are shown.

A clone that expresses the proteins rLiPO-Ct-Q (pPQI) is used as the initial vector, and the fragments of DNA that encode the proteins rLiPO-Ct-Q, rLiP2a-Q, rLiP2b-Q, rLiH2A-Ct-Q and rLiH2A-Nt-Q are added sequentially using appropriate restriction sites.

After each cloning step, the correct orientation of each one of the inserts is deduced from the size of the expression products, and finally the complete nucleotide sequence of the final clone pPQV is determined and the amino acid sequence deduced from the sequence represented in Figure number 3.

The polypeptide generated has a molecular mass of 38 kD, with an isoelectric point of 7.37, including spacer sequences encoding proline, underlined in Figure number 3.

The aim of doing this is to efficiently separate the antigenic domains and avoid possible tertiary conformations that could interfere with the stability and antigenicity of the final product.

The expression and recovery of each of the intermediate products is shown in figure number 4, boxes A and B. As was expected, after each addition, the size of the expression product in the vector pMAL gradually increases until reaching a molecular weight of 80 kDa, observing a certain degree of rupture during purification.

The chimeric gene was also cloned in the plasmid pQE, a vector that allows the expression of proteins with a fragment of 6 histidines at the extreme N-terminus. The resulting clone and the recombinant proteins are denominated pPQ and PQ respectively.

The level of expression of the protein in bacteria transformed with the pPQ plasmid and the purified proteins are shown in Figure number 4, referred to in particular with a D, with the protein PQ, purified by affinity chromatography in denaturising conditions is more stable

that the recombinant protein pPQV represented in Figure number 4, in box D lane 2.

In order to evaluate the final product a series of materials were used, and obviously some techniques, as is described below.

Sera of VL obtained from dogs of different origins are used. The animals are evaluated clinically and analytically in the pertinent laboratory, generally in a Department of Parasitology, and all the positive sera are assayed for indirect immuno-fluoresence (IIF).

The presence of amastigotes of the parasites of these animals is confirmed by direct observation of the popliteal and pleescapular lymph nodes, and a second group of 33 sera of VL originating from other regions, were given a positive diagnosis in the ELISA against total protein extracts of the parasite and/or by IIF.

The sera of dogs affected by different diseases that were not VL are obtained from different origins. Within this group sera from the following infections are found:

Mesocetoides spp.  
Dyphylidium caninum  
Uncinaria stenocephala  
Toxocara canis  
Dipetalonema dranunculoides  
Demodex canis  
Babesia canis  
Ehrlichia canis  
Rickettsia rickettsiae.

The rest of the sera were obtained from dogs that exhibited various clinical symptoms that were not related to any infective process, and the serum controls were obtained from fifteen carefully controlled healthy animals.

Purification of the recombinant proteins expressed by the clones pMA1-c2 is carried out by affinity chromatography on amylose columns, and the purification of

the recombinant protein expressed by the clone pPQ was performed on Ni-NTA resin columns in denaturising conditions (Qiagen).

For analysing the proteins, electrophoresis on 10% polyacrimide gels in the presence of SDS was carried out under standard conditions. Immunological analysis of the proteins separated by electrophoresis was carried out on nitrocellulose membranes to which the proteins had been transferred. The transferred proteins were blocked with dried 5% skimmed milk in a PBS buffer with 0.5% Tween 20.

The filters were sequentially brought into contact with primary and secondary anti-serum in blocking solutions and an immuno-conjugate labelled with peroxidase was used as second antibody, visualising the specific binding by means of an ECL system. Figure 4E shows a Western blot of protein PQ.

The Fast-ELISA was used instead of the classic ELISA, and the sensitisation of the antigen was carried out for 12 hours at room temperature.

The plates were sensitised with 100  $\mu$ l of antigen whose concentration in all cases was 2  $\mu$ g/ml.

After sensitising the wells the plates were incubated for 1 hour with blocking solution (0.5% powdered skimmed milk dissolved in PBS - 0.5% Tween 20 and the sera were diluted three hundred fold in blocking solution).

The wells were incubated with serum for 2 hours at room temperature, and after exposure to the antibody the wells were washed with PBS-Tween 20.

Antibodies labelled with peroxidase were used as second antibodies at a dilution of 1:2000 and the colour of the reaction was developed using the substrate ortho-phenylenediamine, measuring the absorption at 450 nm.

In regard to evaluation of the final product, it should be pointed out that the antigenic properties were determined by means of the pertinent study of the reactivity of the VL canine sera against the chimeric

protein and against each one of the intermediate products in a "Western blot" assay. All the intermediate products maintained their antigenicity as well as did the final pPQV product, throughout the whole of the cloning process (Fig. 4C).

It should also be pointed out that the recombinant protein expressed by the pPQ plasmid was recognised by the VL sera. With a view to analysing with greater precision the antigenic properties of the chimeric protein and the intermediate products, an analysis of the reactivity of a wide variety of VL canine sera was performed by means of a fast-ELISA against the recombinant proteins, as is shown in the section F of Figure number 4. It can be highlighted that the sensitivity of the different intermediate products of cloning increases after each addition step. It should also be pointed out that the protein pQI is recognised by most of the VL sera and the protein PQII equally by most of the sera. This proportion is greater for the protein PQIII and the proteins PQIV, PQV and PQ are recognised by practically all the sera.

According to what has been discussed above, the percentage of recognition shown by the sera was similar both in the case of assaying the chimeric proteins PQV and PQ, and of assaying a mixture of recombinant proteins rLiPO-Ct-Q, rLiP2a, rLiP2b and rLiH2A. It was seen that the antigenic properties of each one of the 5 selected antigenic regions are present in the PQ expression product, and therefore this product can be used for diagnosis instead of a mixture of the antigens expressed individually.

With a view to determining whether the chimeric protein can be used for canine VL serum diagnosis, and according to the pertinent analysis of a wide variety of canine sera against this protein, bearing in mind that according to the clinical characteristics of the animals, the canine sera have been classified into three groups. A

first group consisted of sera from dogs with a real L. infantum infection. A second group was composed of sera of dogs that had various clinical symptoms without being infected with Leishmania, including dogs infected with parasites different to Leishmania, and that could exhibit clinical symptoms that could be confused with those observed during Leishmaniosis.

The third group was made up of control sera, originated from healthy dogs.

In figure number 5 the average values of reactivity are shown for each group of sera, the reactivity of the VL sera reaching an average reactivity value of 0.8 (S.D. = 0.4).

Within this group the reactivity of 12 sera was positive but less than 0.35, while the reactivity of 10 sera reaches values of between 0.35 and 0.5. It was observed that the reactivity of 23 sera varies between 0.5 and 1.0, with 14 sera showing a reactivity greater than 1.0.

The average absorption value of the sera of the second group, that is to say, the group infected with parasites different to Leishmania parasites, is 0.2 (S.D. = 0.05) and the reactivity of the control sera, that is to say, the third group, is 0.1 (S.D. = 0.003). Only two sera from group 2 showed reactivity between 0.35 and 0.40.

The data presented above indicate that the chimeric protein PQ in the FAST ELISA has a sensitivity of 80% for the VL diagnosis, if the cut-off value is defined as the average reactivity value of the sera of group 2 plus three S.D.'s (that is to say 0.35).

The sensitivity of the assayed group reaches 93%, if the cut-off value is defined by the reactivity values of the control group. The protein Q has a specificity of 96% for VL diagnosis, when the cut-off value is defined by the aforementioned sera of group 2. 100% specificity in the assay was reached when the reactivity values of healthy

dogs were considered.

The process to be used is the following:

1.- The microtitre plates are covered with antibodies by incubated 100 µl of a solution that contains 1 µg/ml of antigen dissolved in a buffer PBS - 0.5% Tween 20 - 5% skimmed milk (Buffer A).

The incubation is performed for 12 hours at room temperature, and then the plates are washed three times with the same buffer containing no antigen. The dry antigenated plates could be maintained at room temperature.

2.- A first incubation of the wells was carried out with the serum of animal at a dilution of 1/200 in buffer A. The incubation lasts for 1 hour.

3.- The wells are washed with buffer A, as described in point 1, three times with a wash flask.

4.- They are incubated with a second antibody (IgG labelled with peroxide) diluted 1:2000 in buffer A, carrying out the incubation for 1 hour.

5.- The wells are washed once again with buffer A three times, as was indicated in the third section, that is to say with a wash flask.

6.- The reactivity is revealed using the substrate ortho-phenylenediamine and the absorption measured at 450 nm.

The protein used for the diagnosis extracted from the chimeric gene is identified, and the nucleotide sequence encoding said protein, are as follows:

1	ATG AGA GGA TCT CAC CAC CAC CAC CAC CAC ACG GAT CCG CAT GCG	45
	Met Arg Gly Ser His His His His His His Thr Asp Pro His Ala	
	5 10 15	
46	AGC TCG AAC AAC AAC AAC AAT AAC AAT AAC AAC AAC CTC GGG ATC	90
	Ser Ser Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Gly Ile	
	20 25 30	
91		135

	GAG	GGA	AGG	CCT	TTA	GCT	ACT	CCT	CGC	AGC	GCC	AAG	AAG	GCC	GTC
	Glu	Gly	Arg	Pro	Leu	Ala	Thr	Pro	Arg	Ser	Ala	Lys	Lys	Ala	Val
					35					40					45
5	136														180
	CGC	AAG	AGC	GGC	TCC	AAG	TCC	GCG	AAA	TGT	GGT	CTG	ATC	TTC	CCG
	Arg	Lys	Ser	Gly	Ser	Lys	Ser	Ala	Lys	Cys	Gly	Leu	Ile	Phe	Pro
					50					55					60
10	181														225
	GTG	GGC	CGC	GTC	GGC	GGG	ATG	ATG	CGC	CGC	GGC	CAG	TAC	GCT	CGC
	Val	Gly	Arg	Val	Gly	Gly	Met	Met	Arg	Arg	Gly	Gln	Tyr	Ala	Arg
					65					70					75
15	226														270
	CGC	ATC	GGT	GCC	TCT	GGC	GCC	CCC	AGG	ATT	TCA	GAA	TTC	TCC	GTG
	Arg	Ile	Gly	Ala	Ser	Gly	Ala	Pro	Arg	Ile	Ser	Glu	Phe	Ser	Val
					80					85					90
20	271														315
	AAG	GCG	GCC	GCG	CAG	AGC	GGG	AAG	AAG	CGG	TGC	CGC	CTG	AAC	CCG
	Lys	Ala	Ala	Ala	Gln	Ser	Gly	Lys	Lys	Arg	Cys	Arg	Leu	Asn	Pro
					95					100					105
25	316														360
	CGC	ACC	GTG	ATG	CTG	GCC	GCG	CGC	CAC	GAC	GAC	GAC	ATC	GGC	ACG
	Arg	Thr	Val	Met	Leu	Ala	Ala	Arg	His	Asp	Asp	Asp	Ile	Gly	Thr
					110					115					120
30	361														405
	CTT	CTG	AAG	AAC	GTG	ACC	TTG	TCT	CAC	AGC	GGC	GTT	GTG	CCG	AAC
	Leu	Leu	Lys	Asn	Val	Thr	Leu	Ser	His	Ser	Gly	Val	Val	Pro	Asn
					125					130					135
35	406														450
	ATC	AGC	AAG	GCG	ATG	GCA	AAG	AAG	AAG	GGC	GGC	AAG	AAG	GGC	AAG
	Ile	Ser	Lys	Ala	Met	Ala	Lys	Lys	Lys	Gly	Gly	Lys	Lys	Gly	Lys
					140					145					150
40	391														495
	GCG	ACA	CCG	AGC	GCG	CCC	GAA	TTC	GGA	TCC	TCT	AGA	CCC	ATG	TCC
	Ala	Thr	Pro	Ser	Ala	Pro	Glu	Phe	Gly	Ser	Ser	Arg	Pro	Met	Ser
					155					160					165
45	496														540
	ACC	AAG	TAC	CTC	GCC	GCG	TAC	GCT	CTG	GCC	TCC	CTG	AGC	AAG	GCG
	Thr	Lys	Tyr	Leu	Ala	Ala	Tyr	Ala	Leu	Ala	Ser	Leu	Ser	Lys	Ala
					170					175					180
50	541														585
	TCC	CCG	TCT	CAG	GCG	GAC	GTG	GAG	GCT	ATC	TGC	AAG	GCC	GTC	CAC
	Ser	Pro	Ser	Gln	Ala	Asp	Val	Glu	Ala	Ile	Cys	Lys	Ala	Val	His
					185					190					195
55	596														630
	ATC	GAC	GTC	GAC	CAG	GCC	ACC	CTC	GCC	TTT	GTG	ATG	GAG	AGC	GTT
	Ile	Asp	Val	Asp	Gln	Ala	Thr	Leu	Ala	Phe	Val	Met	Glu	Ser	Val
					200					205					210



	641														675
	ACG	GGA	CGC	GAC	GTG	GCC	ACC	CTG	ATC	GCG	GAG	GGC	GCC	GCG	AAG
	Thr	Gly	Arg	Asp	Val	Ala	Thr	Leu	Ile	Ala	Glu	Gly	Ala	Ala	Lys
					215					220					225
5															
	676														720
	ATG	AGC	GCG	ATG	CCG	GCG	GCC	AGC	TCT	GGT	GCC	GCT	GCT	GGC	GTC
	Met	Ser	Ala	Met	Pro	Ala	Ala	Ser	Ser	Gly	Ala	Ala	Ala	Gly	Val
					230					235					240
10															
	721														765
	ACT	GCT	TCC	GCT	GCG	GGT	GAT	GCG	GCT	CCG	GCT	GCC	GCC	GCC	GCG
	Gly	Asp	Ala	Ala	Pro	Ala	Ala	Ala	Ala	Ala	Lys	Lys	Asp	Glu	Pro
					245					250					255
15															
	766														810
	AAG	AAG	GAC	GAG	CCC	GAG	GAG	GAG	GCC	GAC	GAC	GAC	ATG	GGC	CCC
	Thr	Ala	Ser	Ala	Ala	Glu	Glu	Glu	Ala	Asp	Asp	Asp	Met	Gly	Pro
					260					265					270
20															
	811														855
	TCT	AGA	GTC	GAC	CCC	ATG	CAG	TAC	CTC	GCC	GCG	TAC	GCC	CTC	GTG
	Ser	Arg	Val	Asp	Pro	Met	Gln	Tyr	Leu	Ala	Ala	Tyr	Ala	Leu	Val
					275					280					285
25															
	856														900
	GCG	CTG	TCT	GGC	AAG	ACG	CCG	TCG	AAG	GCG	GAC	GTT	CAG	GCT	GTC
	Ala	Leu	Ser	Gly	Lys	Thr	Pro	Ser	Lys	Ala	ASP	Val	Gln	Ala	Val
					290					295					300
30															
	901														945
	CTG	AAG	GCC	GCC	GGC	GTT	GCC	GTG	GAT	GCC	TCC	CGC	GTG	GAT	GCC
	Leu	Lys	Ala	Ala	Gly	Val	Ala	Val	Asp	Ala	Ser	Arg	Val	Asp	Ala
					305					315					315
35															
	946														990
	GTC	TTC	CAG	GAG	GTG	GAG	GGC	AAG	AGC	TTC	GAT	GCG	CTG	GTG	GCC
	Val	Phe	Gln	Glu	Val	Glu	Gly	Lys	Ser	Phe	Asp	Ala	Leu	Val	Ala
					320					325					330
40															
	991														1035
	GAG	GGC	CGC	ACG	AAG	CTG	GTG	GGC	TCT	GGC	TCT	GCC	GCT	CCT	GCT
	Glu	Gly	Arg	Thr	Lys	Leu	Val	Gly	Ser	Gly	Ser	Ala	Ala	Pro	Ala
					335					340					345
45															
	1036														1080
	GGC	GCT	GTC	TCC	ACT	GCT	GGT	GCC	GGC	GCT	GGC	GCG	GTG	GCC	GAG
	Gly	Ala	Val	Ser	Thr	Ala	Gly	Ala	Gly	Ala	Gly	Ala	Val	Ala	Glu
					350					355					360
50															
	1081														1125
	GCG	AAG	AAG	GAG	GAG	CCC	GAG	GAG	GAG	GAG	GCC	GAT	GAT	GAC	ATG
	Ala	Lys	Lys	Glu	Glu	Pro	Glu	Glu	Glu	Glu	Ala	Asp	Asp	Asp	Met
					365					370					375
55															
	1136														1170
	GGC	CCC	GTC	GAC	CTG	CAG	CCC	GCC	GCT	GCC	GCG	CCG	GCC	GCC	CCT
	Gly	Pro	Val	Asp	Leu	Gln	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Ala	Pro
					380					385					390

1171  
 AGC GCC GCT GCC AAG GAG GAG CCG GAG GAG AGC GAC GAG GAC GAC 1215  
 Ser Ala Ala Ala Lys Glu Glu Pro Glu Glu Ser Asp Glu Asp Asp  
 395 400 405  
 5  
 TTC GGC ATG GGC GGT CTC TTC TAAGCGACTC GCCATCTCTT 1256  
 Phe Gly Met Gly Gly Leu Phe  
 410 412  
 10  
 1258  
 AGCCTCCTTG TGGTGCCTT GAGGTGCTCT CGCTCTGCTT CTCCTTGCAG 1306  
 15  
 1307  
 TGTGGCTGA CTCTGGCGGG TATGTGCCGT CGCATTACAC CCACCTCTCC 1356  
 20  
 1357  
 CACCCCTTTG CCCTACGCGC TCGCATGCGC AATCCGTGAA TCATCGAGGG 1406  
 1407  
 AAGTCTCTCT GGGTGGCAGT GGGTAAGCTT 1436  
 25  
 (SEQ ID NO.1 and SEQ ID NO.2)

It is not considered necessary to extend this description in order that someone skilled in the art can understand the scope of the invention and the advantages that it confers.

The materials, form, size and disposition of the elements are susceptible to change, provided it does not suppose a change in the essence of the invention.

The terms in which this disclosure has been written should always be considered as broad in nature and not limiting.

#### Vaccine against Leishmania

#### BACKGROUND OF THE INVENTION

The protozoan parasites of the genus *Leishmania* are responsible for causing leishmaniasis, a symptomatically complex disease which essentially affects men and animals in tropical and subtropical regions. It is estimated that the number of new cases of human visceral leishmaniasis can reach the number of 500,000, there being a minimum of several tens of millions of persons affected. Additionally

the number of cutaneous and mucocutaneous leishmaniasis can be of the order of 2.000.000 per year (Modabber., 1990). Although the persons at risk of contracting the different types of leishmaniasis can be estimated in about 5 350 million, the number of persons with real infection can be much higher, due to the fact that there are no clear estimations of the real cases of asymptomatic infections and because of the existence of cryptic infections. In fact, leishmaniasis can be considered within the global 10 context as an infection/ disease of endemic nature, situated between the 4<sup>th</sup> and 5<sup>th</sup> place in the ranking of parasitic diseases with world-wide repercussion.

Three main forms of leishmaniasis can be distinguished: cutaneous, mucocutaneous and visceral, the 15 characteristics of which mostly depend upon the localisation of the parasite, the species to which it belongs and the clinical manifestations it produces. The species distributed along Asia and certain regions in the Mediterranean area bring about the presence of the 20 cutaneous form, with localised ulceration which, in many cases, heal spontaneously. These manifestations are caused by *L. major* and *L. tropica*. *L. aethiopica* (Mediterranean, Asia, Africa) also induces the cutaneous form of leishmaniasis, although its manifestation is more diffuse. 25 In America, the species *L. mexicana* produces the cutaneous form with a generalised localisation that does not usually heal spontaneously. The mucocutaneous form of the disease in humans is caused by *L. brasiliensis* and is characterised by the presence of cutaneous lesions in 30 oronasal and pharyngeal regions, bringing about the destruction of the mucosae. In America, Europe, Africa and Asia, the most frequent form of leishmaniasis is the visceral form, caused by *L. chagasi*, *L. donovani* and *L. infantum*. This form of leishmaniasis is characterised by 35 clinical symptoms associated to fever, anaemia and an intense hepato/splenomegalia, which is lethal if it is not

treated suitably at the right time. In the advanced form of the disease, the host is incapable of developing an effective immune response. All of these forms of leishmaniasis are also detected in canids and some rodents which, in fact, constitute the main reservoirs of the parasite. The health problem generated by *L. infantum* in the Mediterranean basin is serious because there is a high incidence of the infection / disease in dogs, and the vector insect is very extended. It is calculated that between 7% and 20% of all canids are infected by *Leishmania*, reaching 30%, in some areas of Spain where it is endemic. This fact constitutes a serious veterinary problem which additionally increases the risk of contagion, fundamentally by immunodepressed persons. In Europe, there are some 11 million dogs at risk of infection by *Leishmania*.

*L. infantum*, like the rest of the species in the genus has a dimorphic biological cycle. The intermediate hosts are insects of the Psychodidae family, genus *Phlebotomus*. In the Mediterranean area of Europe, it has been demonstrated that the species *P. arias* and *P. perniciosus* are the main vectors, although the vectors *P. papatosi*, *P. longicuspis* and *P. sergenti* are also present. When the parasite is ingested by the vector together with the blood of a vertebrate host, it places itself in the gut in an extracellular form, it transforms into a promastigote and it divides. The infective forms migrate towards the pharynx and the proboscis, from where they will be inoculated into a new vertebrate host. The promastigotes are characterised in that they have a flagellum and an elongated shape of some 15 to 20  $\mu\text{m}$  in length, with a rounded posterior end and a sharp anterior end. The nucleus is situated in central position and the kinetoplast at the anterior end. In culture media, the parasites exhibit a certain degree of morphological variability. After the inoculation of the promastigotes in

the skin of the vertebrate host, the establishment, or not, of the infection depends essentially upon two factors: the existence of a suitable cell population - macrophages- and other cells of the phagocytic mononuclear system, and the ability of the parasite to survive and multiply itself in the interior of these cells.

The first step in the penetration of *Leishmania* into macrophages is the approximation and adherence to the plasma membrane of the target cell. *In vitro* studies seem to indicate that there is no direct chemotactic attraction of the promastigotes over the macrophages. Within the environment of tissues, free promastigotes activate complement by the alternative pathway, bringing about the formation of a concentration gradient of fraction C5a, which attracts macrophages and other inflammatory cells towards the site of inoculation. Once the promastigote is within a parasitophorous vacuole, the lysosomes fuse to it forming a phagolysosome. In infections caused by other micro-organisms, the phagolysosome is the organelle responsible for the lysis and elimination by means of several mechanisms such as the production of toxic oxygen radicals, by an oxidative metabolic process, the action of hydrolytic lysosomal enzymes, cationic proteins and low pH. The survival of the parasite in the phagolysosome is a function of its ability to resist and avoid said mechanisms.

The existence of an immune response against parasitisation by *Leishmania* which is both humoral and cellular was discovered from the first moments in which the disease was studied, and has been revised in numerous occasions. The type of humoral response depends upon the form of leishmaniasis. In the cutaneous form, the humoral response is very weak, whereas in the visceral type a high antibody response is observed. In the cutaneous affections there is a remarkable cell-mediated response, detectable both *in vivo* by means of delayed type hypersensitivity

tests (DTH), as well as *in vitro* by means of lymphoblastic transformation tests and macrophage migration inhibition tests. In these cases the titre of serum antibodies is normally low and directly related to the seriousness of the process. Once the amastigotes are within the macrophages, the resolution of the infection depends essentially upon the cell-mediated immune mechanisms. The cellular response is determined by the joint action of macrophages, B cells, several sub-populations of T-cells, and the different lymphokines secreted by all of them. The parasitised macrophage processes the *Leishmania* antigens and expresses them on its surface by a process mediated by the class II Major Histocompatibility Complex (MHC-II). Additionally, the macrophage secretes IL-1, which acts as a second activating signal for the T-lymphocyte. In humans, visceral leishmaniasis or kala-azar is characterised by a weakened or absent cellular response, detectable both by the absence of delayed hypersensitivity (DTH) and by cell proliferation methods. Absence of proliferation of T-cells is detected even in the presence of mitogens such as concanavalin A or phytohaemagglutinin and inhibition in the production of IL-2 by stimulated T-cells.

In mice, the population of T-lymphocytes (CD4 phenotype) is heterogeneous and can be divided into at least two sub-populations according to the lymphokines they produce. These cells are essential in the development of protective immunity against cutaneous leishmaniasis (sub-population Th-1) and are at the same time involved in the suppression of the protective immune response (sub-population Th-2), T cells induced in resistant mice C57BL/6 or cured BALB/c mice are predominantly of the Th-1 type, whereas the cells in uncured BALB/c mice are of the Th-2 type. In general, the lymphokines secreted by these cells favour the development of the cell line which produces them and has an antagonic effect on the

development of the other sub-population. Thus, IL-4 and IL-10 produced by Th-2 cells contribute to the progression of the infection, favouring the development of this line. Additionally, they can act directly on the macrophage, not permitting its activation. However, in mice susceptible of infection by *Leishmania*, deficient in the gene which encodes IL-4, contradictory results have been obtained. In some cases it has been observed that the absence of this cytokine redirects the response and increases the resistance to the infection whereas in others no differences are observed in the level of infection of the mice. In genetically resistant mice it has been observed that the absence of expression of the genes of IFN- $\gamma$  or its receptor, CD40 or the ligand of CD40, increases the susceptibility to the infection. The interaction of CD40 and its ligand is necessary for the production of the cytokine IFN- $\gamma$  necessary to direct the response towards Th-1. Mice with a resistant genetic base, which develop a Th-1 type response, become susceptible if they are deficient in the expression of IL-12., developing a Th-2 type response. Recent data suggests that the production of IL-12 is important to direct the response towards Th-1, and that the absence of IL-4 can avoid the Th-2 response.

There are a large number of *Leishmania* proteins which have an antigenic character essentially characterised by "Western Blot" methods. In the serum of patients and dogs infected by *Leishmania* it has been possible to detect the presence of antibodies against membrane proteins such as gp63, gp 46, PSA and KPM-11. Additionally several antigens of cytoplasmatic intracellular localisation have been characterised such as: Hsp70; Hsp83; LIP2a, LIP2b, LILIP0, H2A, H3 and a protein related to kinesin, K39 of *L. chagasi*. The reactivity of the antibodies, which recognise conserved proteins present in the serum of dogs infected by *L. infantum* is directed towards the least conserved areas of

these proteins. Some of the membrane proteins are very antigenic in natural infections. In all the cases of natural infection there is a great restriction in the humoral response against the proteins because the antibodies developed during the infective process recognise very restricted areas of the same. The levels of IgG normally correspond to the intensity of the infection reflect the degree and the duration of antigenic stimulation determined by the parasitic load. A *Leishmania* antigen homologous to the type C kinase receptors (LACK) has recently been described which produces an early response of the Th-2 type. In mice transgenic for the LACK antigen and with a genetic background susceptible to the infection, the induction of tolerance to this antigen protects against the infection by *Leishmania major*. The anti-*Leishmania* antibodies can destroy the promastigotes *in vitro* in the presence of complement, promote phagocytosis and induce the adherence of several particles to the surface of promastigotes and amastigotes.

The pathologic reaction seems to go in parallel with the density of parasitised macrophages. In visceral leishmaniasis the macrophages generally distribute themselves in a diffuse manner throughout the different organic tissues. The type of inflammation is constituted by an important cellular infiltrate with a predominance of lymphocytes and plasmatic cells together with hyperplasia of phagocytic cells. The inflammation brings about alterations in the physiology of the affected organs producing serious systemic alterations. In some occasions local granulomatous inflammation occurs, with appearance of granulomae and microgranulomae in the different organs. These granulomae are constituted by macrophages and histiocytes (affected by parasites or not) surrounded by plasmatic cells and lymphocytes and, in some cases, by fibroblasts. This inflammatory process is accompanied by an organic reaction with the appearance of



characteristic lesions in the affected organs. Some authors have found deposits of amyloid substance in virtually the totality of the organs. Some authors have formulated the hypothesis that the damages produced by the disease are not directly attributable to the aethiologic agent but to the organic reaction triggered.

#### **Vaccine against Leishmania**

The intense immunity which follows the recovery from cutaneous leishmaniasis has given a great impulse to the development of prophylactic vaccines against this disease. This immunity is derived from the induction of a T response which has associated to it the production of inflammatory cytokines which activate macrophages and destroy the parasites. The immunological memory in the cases of infection is probably maintained by the persistent presence of the parasite in the host in a process known as concomitant immunity.

The first studies regarding vaccination against Leishmania in the decade of the 40's used live parasites as immunogens. These studies led to the production of vaccines which produced significant protection against subsequent re-infection. However, the knowledge of the possibility that live organisms could produce real infections led to such vaccination programmes not to take place for very long and, on the contrary, interest focused upon vaccines based upon dead parasites. These studies provided the first evidence on the possibility of producing effective vaccines by inoculation of parasites.

The clinical trials which used immunisation with dead *Leishmania* promastigotes also began in the decade of the 40's. These vaccines yielded remarkable successes as a certain degree of protection was observed, which could oscillate between 0 and 82% depending on the population. These vaccines had a smaller effect than live parasite vaccines. The isolation of avirulent clones of *L. major*

which protect mice against infection has also demonstrated that an attenuated vaccine is possible. However, the ignorance of the mutations which lead to the loss of virulence and the risk of production of virulent revertants make this type of vaccination currently unacceptable.

Recently there has been an important progress towards the identification of molecularly defined candidate vaccines, such as gp63 , gp46/M2 , the surface antigen related to the latter antigen known as PSA-2 and the proteins dp72 and gp70-2, the LACK protein and Kmp11. Specifically, the T epitopes present in protein gp63 have been identified, resulting in that only some of them are capable of inducing a T response, both of Th-1 as of Th-2. These antigens induce significant protection in model animals when they are administered with adjuvants. Protein PSA-2 of *Leishmania* is capable of protecting against infection by *L. major* by inducing a Th-1 response. To evaluate the mechanism of protection of this protein as a vaccine against *Leishmania* in humans, its ability to induce T-cell proliferation was studied, in patients which had suffered leishmaniasis and had recovered from it. It was observed that the protein is capable of bringing about a strong proliferation of the T-cells of these individuals, but not of controls with no prior history of infection. The response was of the Th-1 type, as was demonstrated by the cytokine induction pattern.

Sub-unit vaccines have focused strongly on protein antigens because they are easy to identify, isolate and clone. However, it is necessary to take into account that not all potential vaccine molecules have to be proteins. In fact, lipophosphoglycan (LPG) plays an essential role in the establishment of infection. Vaccination with LPG can protect against infection with *L. major*. In spite of the existence of a dogma which states that T-cells do not recognise non-proteinaceous antigens, the LPG molecule

seems to be presented to T-cells by Langerhans cells of the skin.. Additionally, there is evidence which has demonstrated that microbial glycolipids and other non-proteinaceous molecules can recognise T-cells when they are presented via the CD-1 route. Although there is no clear evidence that protein KMP11 associated to LPG induces a protective response, it has been proved that the proteinaceous fraction associated to LPG is capable of inducing a T response and IFN- $\gamma$ , whereas the LPG fraction without protein is not.

It is normally accepted that sub-unit vaccines although protective, only induce a short term immunity. This problem may not be important in endemic areas, where the individuals can be periodically boosted by cause of natural infections. A major problem in the use of sub-units may arise from the fact that there may not be a response to a single antigen in a genetically diverse population. A cocktail of antigens containing B and T inducers may overcome this drawback. It has recently been published that an extract of membrane proteins of *Leishmania infantum*, when injected intraperitoneally, is capable of conferring protection against the virulent promastigote forms of this parasite, and that this protection is greater when the proteins are encapsulated in positively charged liposomes. Adjuvanticity and protective immunity elicited by *Leishmania donovani* antigens encapsulated in positively charged liposomes.

Vaccination with nucleic acids carrying genes which encode *Leishmania* proteins involves the administration of genetic material of the parasite to the host. This DNA is taken up by the cells and is introduced into the nucleus where it is transcribed and subsequently translated in the cytoplasm. The advantage of this type of vaccination is that it is possible to direct the immune response by means of the MHC-I or the MHC-II route. The antigens produced intracellularly are processed in the cell and the peptides

generated are presented on the cell surface in association with MHC-I molecules. The consequence would be that these molecules would give rise to the induction of cytotoxic T-cells. The antigens produced in an extracellular environment would be specially taken up by specialised antigen-presenting cells, processed and presented on their surface bound to MHC-II molecules, resulting in the induction and activation of CD4+ cells which secrete cytokines which regulate the effector mechanisms of other cells of the immune system.

The first DNA vector to be administered as a vaccine contained the gp63 gene. Also, the PSA-2 gene has been introduced into a plasmid and it has been observed that it generates a Th-1 response and induction of protection. Vaccination with DNA plasmids which contain Ag-2 induce a Th-1 response and protect against infection with *L. major*, while Ag-2 in stimulatory immune complexes elicits a combined Th-1 and Th-2 response and does not protect despite the fact that IFN- $\gamma$  is induced. Equally, the gene encoding the LACK protein has been administered subcutaneously to BALB/c mice, in an expression vector which expresses the protein under the control of the cytomegalovirus promoter, and protection against infection with *L. major* has been observed. In almost all cases in which DNA has been administered, the route has been intramuscular, although intradermal injection of particulate DNA must also be explored, as it requires a smaller amount of DNA. Other immunisation systems use vectors such as *Salmonella*, BCG or *Vaccinia* virus. It is interesting to remark that the inclusion of the gp63 gene in BCG is capable of inducing protection against *L. major*.

The gene which encodes protein gp63 has also been introduced into gene delta araC under the control of the rac promotor in an attenuated *Salmonella typhimurium*. Oral administration of  $1 \times 10^9$  colonies of the transformed bacterium induces a T response within the scope of both

Th-1 and of cytotoxic cells against mastocytoma cells which express gp63. Protein gp63 in the form of gp63-ISCs complex induces protection in mice, evidenced by the reduction in inflammation and suppression of lesions.

5 In serum, there are antibodies of the IgG2a type and, additionally, it is possible to observe a Th-1 response by induction of IL-2, IFN- $\gamma$  and IL-10. No DTH response was observed. *Salmonella typhi* Nramp 1 transformed with gp63 elicits a Th-1 response with induction of IL-2 and IFN- $\gamma$ ,

10 and a strong resolution of the lesions is detected. A protein of *L. pifanoi* known as P-4 induces significant protection against infection by *Leishmania*. Recent studies in humans with cutaneous leishmaniasis indicate that this protein or the peptides derived from it are capable of

15 making T cells proliferate. There is no induction of IL-4, whereas IFN- $\gamma$  is induced. Aro-A and aro-D mutants of *Salmonella typhi* transformed with IL-2, IFN- $\gamma$  and TNF- $\alpha$  administered orally may serve as therapeutic systems against infection by *L. major*. It is interesting to

20 observe that in these patients there is a greater induction of iNOS. The gp63 gene has also been cloned in Aro-A and Aro-D mutants, and it has been observed that after oral administration, the protein encoded is capable of inducing significant protection against infection with

25 *L. major*. This same protein is capable of inducing protection when it is administered fused to several promoters in specific varieties (GID105 and GID106) of *Salmonella*.

An artificial protein denominated Q has recently

30 been described by our group, which is composed of several antigenic fragments from 4 proteins of *Leishmania infantum* (more specifically, Lip2a, Lip2b, P0 and H2A), which, after being used as antigen, has proven to have an important value for the diagnosis of canine leishmaniasis,

35 with a 93% sensitivity and a 100% specificity when compared with sera of control animals which are not

infected. Equally, our group has demonstrated that protein hsp70 of *Leishmania infantum* is an important target of the immune response in infections caused by infection with this parasite.

5           With the object of exploring the possibility that protein Q may be used to design protection systems against infection by *Leishmania infantum*, both on its own as in combination with Hsp70, three series of experiments were designed using the hamster as a model. An experiment was  
10           designed to check whether immunisation with Protein Q protected the animals against infection on the short term, another to check whether immunisation protected them on the long term and the third was to check this protective effect after immunisation with the two proteins together.  
15           It was thereafter observed both from the short term analysis as well as from the long term analysis, that protein Q was capable of eliciting an immune response which reduces the parasitic load both in the Liver and in the Spleen after infection by *Leishmania infantum* in most  
20           of the immunised animals, and that immunisation with the proteins Q+Hsp70 also induced a significant response against both proteins and lead to a significant reduction of the parasitic load in most of the immunised animals.

#### 25           **Example 1: Immunisation with Protein Q**

          4 animals were immunised with 5 micrograms of protein Q dissolved in 40 microlitres of Freund's adjuvant, and another 4 animals were immunised with the same amount of adjuvant emulsified with 40 microlitres of  
30           PBS saline solution without the protein. In the first immunisation, Freund's complete adjuvant was employed combined with the protein, while in the two subsequent immunisations, incomplete Freund's adjuvant was used mixed with the protein in the same proportion of  
35           protein/adjuvant. Three intraperitoneal immunisations were carried out at 15 day intervals. Starting from the second

week after each immunisation and throughout the whole period of immunisation, blood samples were extracted to measure the humoral response against protein Q in ELISA assays. It was observed that already in the second week after the first immunisation there is a positive IgG response against protein Q, and that this response was high after the second week after infection, and increased with time of immunisation reaching titres of 1/100.000. Equally, it was observed that immune response against protein Q was not modified significantly after the infection with the parasite Fig. 1.

Fifteen days after the third immunisation, the animals were infected with a dose of  $10^5$  promastigote parasites, differentiated from infective amastigotes originating from an infected hamster. It had been previously checked that the inoculum was capable of inducing a strong parasitemia together with the disease four months after having administered the parasites, in 100% of the animals infected. Table 1 indicates the level of parasitemia per mg of tissue both in liver and in the spleen of the control and the vaccinated animals. It is possible to observe that in all of the vaccinated animals the parasitic load in the liver decreases with respect to the controls, and that this happens in a very significant manner in 75% of them. When the parasitic load in the spleen is examined, it possible to observe that also in 75% of the animals this load was significantly lower than that of the controls, the RPL reaching 83%-86%. The animal in which the RPL was 20% in the liver, had a 48% one in the spleen.

Table 1. Parasitic load in the liver and spleen of hamsters vaccinated with protein Q via the intraperitoneal route. After four weeks of infection, the parasitic load was measured by the method of limit dilutions (short term). The parasitic load is expressed as parasites per milligram of tissue. RPL = reduction in parasitic load in %.

10	Hamster immunized with the Q protein				
	<b>Hamster</b>	<b>Liver</b>	<b>(RPL)</b>	<b>Spleen</b>	<b>(RPL)</b>
	1	4 ± 1	(71%)	49 ± 3	(83%)
	2	3 ± 2	(78%)	39 ± 2	(86%)
	3	5 ± 1	(64%)	50 ± 4	(83%)
15	4	11 ± 3	(20%)	153 ± 19	(48%)

The numbers represent the mean of three determinations

#### Controls

4 hamsters 14 ± 5                      295 ± 30

20 The number represent the mean of the 4 animals

#### Example 2

In order to verify the effect of vaccination with protein Q on the reduction of the parasitic load on the long term, using another route of inoculation, 4 animals were injected subcutaneously with 5 micrograms of protein Q dissolved in 40 microlitres of PBS and mixed with 40 microlitres of Freund's adjuvant. In the first immunisation, Freund's complete adjuvant was employed, while in the two subsequent ones, incomplete Freund's adjuvant was used as indicated above. Vaccination was administered in three doses spaced at 15 day intervals. Fifteen days after the third immunisation they were administered an inoculum of  $10^5$  infective parasites. During all of the immunisation period and throughout the whole of the infection (five months) blood was extracted



to determine the kind of humoral response against protein Q and against the total proteins of the parasite. Figure 2 shows that already after the second week of immunisation, the response against protein Q was positive, as in the previous case, in three of the mice, and that the response against the protein was very high after two weeks of the first immunisation. The response kept on being very high after the remaining immunisations, reaching a titre of 1/75.000 on the week following the third immunisation. In one of the animals the response against protein Q was slower in relation to time, although the response reached the level of that in the other animals by the end of the experiment. Consequently, from the data derived both from example 1 and from example 2, it is possible to conclude that the degree of the immune response against the protein, by both routes, intraperitoneal and subcutaneous, is very rapid, although the response via the intraperitoneal route attained higher titres in the same times (1/75.000 versus 1/30.000). Figure 3 indicates the response against protein Q in the control animals. It is possible to observe that reactivity against this protein is detected on the 12-14th week after infection, which is when the first symptoms attributable to a potential leishmaniasis begin to be detected in the animals infected. Table 2 shows the levels of parasitemia in the liver and spleen of the control and vaccinated animals. It can be seen that 50% of the animals were protected at the level of the liver, in the sense that the reduction in the level of parasitemia was very high (87-89%). One of the animals was not protected, whereas in another of the animals the reduction of the parasitic load was of 22%. On the contrary, the reduction of the parasitic load was of 98-99% in 100% of the animals at the level of the spleen.

Table 2. Parasitic load in the liver and spleen of hamsters vaccinated with protein Q by the subcutaneous route. After 20 weeks of infection, the parasitic load was measured by the method of limit dilutions (long term). The parasitic load is expressed as parasites per milligram of tissue. RPL = reduction in parasitic load in %.

Hamsters immunized with the Q protein

Hamster	Liver	(RPL)	Spleen	(RPL)
1	$1.4 \times 10^6$	(22%)	$1.0 \times 10^7$	(98%)
2	$2.0 \times 10^5$	(89%)	$4.9 \times 10^5$	(99.9%)
3	$2.4 \times 10^5$	(87%)	$3.3 \times 10^5$	(99.9%)
4	$2.4 \times 10^6$	(0%)	$6.3 \times 10^5$	(99.9%)

The number represent the mean of three determinations

Controls

4 hamsters.  $1.8 \times 10^6 \pm 1.2 \times 10^5$   $5.2 \times 10^8 \pm 2.6 \times 10^7$

The numbers represent the mean of the parasitic load of the 4 animals

With the object of testing if protein Q could be used to design protection systems in formulations which contained protein LiHsp70 of *Leishmania infantum*, an experiment was carried out in Balb/c mice. It was observed that after immunisation, the parasitic load both in the liver as in the spleen was reduced significantly, being in some of the animals, four orders of magnitude lower.

### Example 3: Immunisations with protein Q + protein Hsp70 in Freund's Adjuvant.

Each one of 4 hamsters were injected intraperitoneally with 5 micrograms of protein Q and 5 micrograms of protein LiHsp70 dissolved in 40 microlitres of PBS and emulsified in 40 microlitres of Freund's adjuvant. In the first immunisation, Freund's complete adjuvant was

employed, while in the two subsequent ones, incomplete Freund's adjuvant was used as indicated above. Vaccination was administered in three doses spaced at 15 day intervals.

Fifteen days after the third immunisation they were administered an inoculum of  $10^6$  infective parasites via the intracardiac route and were sacrificed at week 22. Every two weeks, for all of the immunisation period and throughout the whole of the infection, blood was extracted from them to determine the degree of humoral response against protein Q and against protein LiHsp70.

The relative parasitic load between the mice immunized with the Q protein plus LiHsp70 is shown in Table 3. It was observed that all the animals were highly protected and in some of them, in the spleen, the reduction was close to two-three orders of magnitude.

Table 3. Relative parasitic load of Balb/c mice immunized with the Q plus LiHsp70 protein after 4 month of infection.

Mice immunized with the protein Q and LiHsp70

Mouse	Liver	(RPL)	Spleen	(RPL)
1	$1.5 \times 10^3$	(97%)	$1.5 \times 10^4$	(99%)
2	$0.9 \times 10^3$	(98%)	$1.4 \times 10^3$	(99%)
3	$2.0 \times 10^4$	(60%)	$5.6 \times 10^4$	(99%)
4	$0.8 \times 10^4$	(84%)	$1.2 \times 10^5$	(96%)

The numbers represent the mean of three determinations.

Controls

4 mice  $5.1 \times 10^4 \pm 2 \times 10^3$   $3.2 \times 10^6 \pm 8 \times 10^4$

The numbers represent the mean of the parasitic load of the 4 animals.

Tables 4 and 5 shows that all the animals from Examples 1 and 2 respond immunologically to protein Q, and that starting from the second week after immunisation the response against protein Q was high and this response increased after the second immunisation (week 4). Table 6 shows that the response against protein LiHsp70 throughout the whole time of the experiment was also positive, although lower than the response in Example 3 against protein Q.

Tables 4 and 5. Show the immune response in 4 hamsters injected intraperitoneally with 5 micrograms of protein Q (TABLE 4- Example 1, short term) and the immune response in 4 hamsters injected subcutaneously with 5 micrograms of protein Q (TABLE 5 - Example 2, long term).

**TABLE 4: Example 1, short term**

Mice Immunized with the Q protein (Short term)

Immune response against the Q protein

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	0,8	0,2	0,3	0,6
4	1,9	2,3	1,1	2,1
6	3	3	2,4	2,9
Infected				
8	3	3	2,9	3
10	3	3	3	3

The sera (diluted 1/200) showing an optical density of 3 have a titre higher than 1/45.000.

**Control mice**

Immune response against the Q protein (Short term).

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	0	0	0	0
4	0	0	0	0
6	0	0	0	0
8	0	0	0	0
10	0	0	0	0

The sera were diluted 1/200

**TABLE 5: Example 2, long term**

Mice immunized with the Q protein (Long term).

5 Immune response against the Q protein

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	1,8	1,3	1,9	0,4
4	2,1	1,8	2,2	0,7
6	2,5	2,7	2,5	0,5
8	2,8	2,2	2,2	0,8
10	3	2,9	2,5	0,7
12	3	3	3	0,9
14	3	3	3	1
16	3	3	2,9	1,5
18	3	3	3	1,7
20	3	3	3	2,2
22	3	3	3	2,6
24	3	3	3	3
26	3	3	3	3

The sera (diluted 1/200) showing an optical density of 3 have a titre higher than 1/45.000.

#### Control mice

10 Immune response against Q protein (Long term).

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	0	0	0	0
4	0	0	0	0
6	0	0	0	0
8	0	0	0	0
10	0	0	0	0
12	0,2	0,1	0,3	0,1
14	0,3	0,5	0,4	0,2
16	0,4	0,5	0,7	0,3
18	0,9	1,1	1,7	0,6
20	1,1	1,3	1,5	0,8
22	2,5	2,3	2,7	1,9
24	2,3	2,1	1,8	2,2
26	1,9	2,2	2,3	2,7

The sera were diluted 1/200

TABLE 6. Shows the immune response in 4 hamsters injected intraperitoneally with 5 micrograms of protein Q plus 5 micrograms of protein LiHSP 70 (Example 3, long term).

5

Mice immunized with the Q protein + Hsp70  
Immune response against the Q protein

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	0,4	0,6	0,5	0,4
4	1,6	1,1	1,6	1,7
6	3	2	1,9	1,9
8	3	2,4	2,6	2,5
10	3,	2,9	3	2,9
12	2,7	2,9	2,9	2,9
14	2,5	2,6	2,9	2,7
16	2,6	2,5	2,5	2,4
18	2,8	2,7	2,7	2,5
20	2,5	2,8	2,4	2,7
22	2,5	2,4	2,8	2,9

The sera were diluted 1/800

10

#### Control mice

Immune response against the Q protein

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	0	0	0	0
4	0	0	0	0
6	0	0	0	0
8	0	0	0	0
10	0	0	0	0
12	0	0,1	0,2	0,1
14	0,3	0,4	0,2	0,5
16	0,5	0,6	0,7	0,7
18	0,8	1,4	1,1	1,5
20	1,8	1,6	1,8	2,2

The sera were diluted 1/200

15

Mice immunized with the Q protein + Hsp70  
Immune response against the Hsp70 protein

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	0,1	0,2	0,1	0,4
4	0,4	0,6	0,3	0,5
6	0,8	0,7	0,4	0,3
8	0,7	1,1	1,2	0,5
10	1,2	1,4	1,5	0,8
12	1,9	1,9	2	1,2
14	2	1,8	2,2	1,7
16	1,9	2	2,2	1,9
18	2,	2,1	2	2
20	2	2,1	2,2	1,9
22	2,4	2,3	2,1	1,9

The sera were diluted 1/800

5

#### Control mice

Immune response against the Hsp70 protein

Week	Mouse 1	Mouse 2	Mouse 3	Mouse 4
2	0	0	0	0
4	0	0	0	0
6	0	0	0	0
8	0	0	0	0
10	0	0	0	0
12	0,1	0	0,3	0
14	0,3	0,2	0,5	0,4
16	0,5	0,6	0,6	0,3
18	0,7	0,6	0,7	0,5
20	1	0,8	0,5	1,2
22	1,7	1,4	0,8	1,1

The sera were diluted 1/200

10

#### Example 4: Immunization with protein Q + BCG in Balb/c mice

Four Balb/c mice were each injected intraperitoneally with 5 micrograms of protein Q and  $10^6$  Colony Forming Units (CFU) of BCG (bacille Calmette-Guérin) dissolved in 40 microlitres of PBS. Immunization was effected in three doses, 15 days apart. 15 days after the third immunization, they were administered an inoculum of infective parasites of  $10^5$  BCN150 of *L. infantum* by the intracardiac route. Every two weeks, throughout the time of immunization and throughout infection, blood samples were taken from them for testing

20

the degree of humoral response to protein Q. The animals were sacrificed at week 8 after infection.

5        Table 7 (a and b) shows that the immunized animals respond positively to protein Q starting from the second week and that the response increases progressively until in many cases it reaches values of 400,000. Table 8 shows the difference in parasitic burden between the liver and spleen of the vaccinated and control animals.

10        Table 7: Immune response to protein Q in Balb/c mice immunized with 5 micrograms of protein Q and  $10^6$  CFU of BCG

Mice 1, 2, 3, 4 immunized

15        Mice 5, 6, 7, 8 unimmunized controls



**Table 7: Reaction to protein Q**

week		Mouse 1	Mouse 2	Mouse 3	Mouse 4
preimmune		0	0	0	0
1st immuniz.					
5	1	0	0.2	0.1	0
2nd immuniz.					
	3	0.5	0.7	0.8	0.9
3rd immuniz.					
	6	1.6	2.1	2.6	2.7
10	7	1.8	2.3	2.4	2.1
	9	2.1	2.6	2.5	1.9
	11	2.7	2.9	3	3
	13	3	3	3	3
week		Mouse 5	Mouse 6	Mouse 7	Mouse 8
preimmune		0	0	0	0
1st immuniz.					
	1	0	0	0	0
2nd immuniz.					
20	3	0	0	0	0
3rd immuniz.					
	6	0	0	0	0
	7	0	0	0	0
	9	0	0	0	0
25	11	0	0	0	0
	13	0	0	0	0

the number 3 is equivalent to overflow in the measurement system

30 the sera were taken at the beginning of each of the the weeks indicated

the 1st immunization was effected on day 0, the 2nd on day 15 and the third on day 30.

Table 8. Parasitic burden in liver and spleen of Balb/c mice vaccinated with protein Q subcutaneously +  $10^6$  of BCG. 8 weeks after infection, the parasitic burden was measured by optical microscopy of tissue impressions by measuring different fields containing 7000 nucleated cells. The parasitic burden is represented as the quantity of parasites per milligram of tissue, having previously calculated that 1 parasite per 1000 nucleated cells is equivalent to an approximate quantity of 210 parasites per milligram of tissue.

RPB = reduction of parasitic burden, %.

	Mouse	Liver	(RPB)	Spleen	(RPB)
15	1	72	(82%)	457	(89%)
	2	40	(90%)	207	(95%)
	3	48	(88%)	n.d.	(100%)
	4	n.d.	(100%)	90	(98%)
20	Controls				
	4 animals. Mean	400 ± 15		4155 ± 30	
	n.d. parasites could not be detected in 5000 nucleated cells				

## Claims:

1. A pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis, formed:

- 5 a) by the protein Chimera Q, or a variant of this protein containing modifications or substitutions of preserved amino acids administered to a subject (human or animal), or
- 10 b) by protein Q in isolated form or combined with any physiological adjuvant by the intraperitoneal, subcutaneous or intramuscular route.

2. A vaccine that is able to stimulate the production of antibodies that recognize the Leishmania parasite, formed

- 15 a) by the protein Chimera Q or a variant of this protein that differs from protein Q in preserved amino acids, administered to a subject (human or animal), or
- 20 b) by protein Q in isolated form or combined with a physiological adjuvant by the intraperitoneal, subcutaneous or intramuscular route.

3. A pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis formed

- 25 a) by protein Q, or a variant of this protein containing modifications or substitutions of preserved amino acids, combined with the protein LiHsp70, complete or fragmented, administered to a subject (human or animal), or
- 30 b) by protein Q in isolated form or combined with a physiological adjuvant, as for example BCG, by the intraperitoneal, subcutaneous or intramuscular route.

4. A pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis, formed

35

- a) by any DNA vector bearing the sequence that codes for the protein Quimera Q, or a variant of that sequence that contains modifications or substitutions of nucleotides that code for preserved amino acids, administered to a subject (human or animal), or
- b) by a DNA vector that contains protein Q combined with a physiological adjuvant, administered by the intraperitoneal, intramuscular or subcutaneous route.

5. A pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis, formed a) by any DNA vector bearing:

- 1) the sequence that codes for the protein Quimera Q, or a variant of that sequence that contains modifications or substitutions of nucleotides that code for preserved amino acids, and
- 2) the sequence of nucleotides that codes for the protein LiHsp70 or variants thereof that differs with respect to preserved amino acids, administered to a subject (human or animal), or
- b) by any vector that contains the DNA sequence that codes for protein Q as defined under a) administered with a physiological adjuvant by the intraperitoneal, intramuscular or subcutaneous route.

6. Protein useful for pharmacological purposes, in particular for the prevention and/or treatment of Leishmaniosis, in particular canine Leishmaniosis, having the amino acid sequence:

Met	Arg	Gly	Ser	His	His	His	His	His	His	Thr	Asp	Pro	His	Ala	Ser
1				5					10					15	
Ser	Asn	Asn	Asn	Asn	Asn	Asn	Asn	Asn	Asn	Asn	Leu	Gly	Ile	Glu	Gly
			20					25					30		
Arg	Pro	Leu	Ala	Thr	Pro	Arg	Ser	Ala	Lys	Lys	Ala	Val	Arg	Lys	Ser
		35					40					45			
Gly	Ser	Lys	Ser	Ala	Lys	Cys	Gly	Leu	Ile	Phe	Pro	Val	Gly	Arg	Val
	50					55					60				

- 59 -

	Gly	Gly	Met	Met	Arg	Arg	Gly	Gln	Tyr	Ala	Arg	Arg	Ile	Gly	Ala	Ser	
	65					70					75					80	
5	Gly	Ala	Pro	Arg	Ile	Ser	Glu	Phe	Ser	Val	Lys	Ala	Ala	Ala	Gln	Ser	
					85					90					95		
	Gly	Lys	Lys	Arg	Cys	Arg	Leu	Asn	Pro	Arg	Thr	Val	Met	Leu	Ala	Ala	
				100					105					110			
10	Arg	His	Asp	Asp	Asp	Ile	Gly	Thr	Leu	Leu	Lys	Asn	Val	Thr	Leu	Ser	
			115				120						125				
	His	Ser	Gly	Val	Val	Pro	Asn	Ile	Ser	Lys	Ala	Met	Ala	Lys	Lys	Lys	
15		130					135					140					
	Gly	Gly	Lys	Lys	Gly	Lys	Ala	Thr	Pro	Ser	Ala	Pro	Glu	Phe	Gly	Ser	
	145					150					155					160	
20	Ser	Arg	Pro	Met	Ser	Thr	Lys	Tyr	Leu	Ala	Ala	Tyr	Ala	Leu	Ala	Ser	
					165					170					175		
	Leu	Ser	Lys	Ala	Ser	Pro	Ser	Gln	Ala	Asp	Val	Glu	Ala	Ile	Cys	Lys	
				180					185					190			
25	Ala	Val	His	Ile	Asp	Val	Asp	Gln	Ala	Thr	Leu	Ala	Phe	Val	Met	Glu	
			195					200					205				
	Ser	Val	Thr	Gly	Arg	Asp	Val	Ala	Thr	Leu	Ile	Ala	Glu	Gly	Ala	Ala	
30		210				215						220					
	Lys	Met	Ser	Ala	Met	Pro	Ala	Ala	Ser	Ser	Gly	Ala	Ala	Ala	Gly	Val	
	225					230					235					240	
35	Thr	Ala	Ser	Ala	Ala	Gly	Asp	Ala	Ala	Pro	Ala	Ala	Ala	Ala	Ala	Lys	
				245						250					255		
	Lys	Asp	Glu	Pro	Glu	Glu	Glu	Ala	Asp	Asp	Asp	Met	Gly	Pro	Ser	Arg	
				260					265					270			
40	Val	Asp	Pro	Met	Gln	Tyr	Leu	Ala	Ala	Tyr	Ala	Leu	Val	Ala	Leu	Ser	
			275					280					285				
	Gly	Lys	Thr	Pro	Ser	Lys	Ala	Asp	Val	Gln	Ala	Val	Leu	Lys	Ala	Ala	
45		290					295					300					
	Gly	Val	Ala	Val	Asp	Ala	Ser	Arg	Val	Asp	Ala	Val	Phe	Gln	Glu	Val	
	305				310					315					320		
50	Glu	Gly	Lys	Ser	Phe	Asp	Ala	Leu	Val	Ala	Glu	Gly	Arg	Thr	Lys	Leu	
					325					330					335		
	Val	Gly	Ser	Gly	Ser	Ala	Ala	Pro	Ala	Gly	Ala	Val	Ser	Thr	Ala	Gly	
				340					345					350			
55	Ala	Gly	Ala	Gly	Ala	Val	Ala	Glu	Ala	Lys	Lys	Glu	Glu	Pro	Glu	Glu	
			355					360					365				
	Glu	Glu	Ala	Asp	Asp	Asp	Met	Gly	Pro	Val	Asp	Leu	Gln	Pro	Ala	Ala	
60		370					375					380					
	Ala	Ala	Pro	Ala	Ala	Pro	Ser	Ala	Ala	Ala	Lys	Glu	Glu	Pro	Glu	Glu	
	385					390					395					400	
65	Ser	Asp	Glu	Asp	Asp	Phe	Gly	Met	Gly	Gly	Leu	Phe					
				405						410							

or a mutant or fragment thereof that can be used for  
generating a protective immune response in a human or  
5 animal against Leishmaniosis.

7. A pharmaceutical composition for the prevention  
and treatment, in humans or animals, of Leishmaniasis,  
comprising the protein of claim 6 or or a mutant or  
10 fragment thereof that can be used for generating a  
protective immune response in a human or animal against  
Leishmaniosis.




8. A vaccine capable of stimulating the production  
15 of antibodies which recognise the Leishmania parasite,  
comprising the protein of claim 6 or or a mutant or  
fragment thereof that can be used for generating a  
protective immune response in a human or animal against  
Leishmaniosis.

20 9. A pharmaceutical composition for the  
prevention and treatment, in humans or animals, of  
Leishmaniasis, comprising antibodies directed against the  
protein of claim 6 or or a mutant or fragment thereof that  
25 can be used for generating a protective immune response in  
a human or animal against Leishmaniosis.

10. Method for the prevention or treatment of  
Leishmaniosis in a human or animal, comprising  
30 administering to the human or animal a pharmaceutical  
composition according to any of claims of claims 1, 3, 4,  
5, 7 or 9.

11. Method for preventing Leishmaniosis in a human  
35 or animal, comprising administering to the human or animal  
a vaccine according to claim 2 or 8.

1/6

*Fig 1a**Fig 1b**Fig 1c*

2/6



*Fig 1d*





Fig 2






4/6



*Fig 3*

**MBP** IEGRPLTPRSAKKAVRKSGSKSAKCGLIFPVGRVGGMMRRGQYARRIGA 50  
 SGAPRISEFSVKAAAQSGKKRCRLNPRTVMLAARHDDDIGTLLKNVTLSHSGVV 104  
 PNISKAMAKKKGGKKGKATPSAPEFGDSSRPMSTKYLAAYALASLSKASPSQAD 157  
 VEAICKAVHIDVDQATLAFVMESVTGRDVATLIAEGAAKMSAMPAASSGAAAGV 211  
 TASAAGDAAPAAAAA~~KK~~DEFEEEEADDDMGPSVRDPMQYLAAYALVALSGKTPSK 265  
 ADVQAVLKAAGVAVDASRVDAVFQEV~~EG~~QSF~~D~~ALVAEGRTKLVGSGSAAPAGAV 319  
 STAGAGAGAVAEAKKEEPEEEEEADDDMGPVDLOPA~~AA~~PAAPSAAAKAAPEESD 374  
 EDDFGMGGLF

*Fig 4a**Fig 4b*

*Fig 4c**Fig 4d**Fig 4e*

6/6

*Fig 4f**Fig 5*

- 1 -

## SEQUENCE LISTING

&lt;110&gt; Laboratorios CBF-Leti

5 <120> Chimeric gene formed of the DNA sequences that encode  
the antigenic determinants of four proteins of  
L. Infantum and protein encoded by said gene, and  
pharmaceutical composition useful for preventing

10 &lt;130&gt; BO 42418

&lt;140&gt; PCT

&lt;141&gt; 1999-12-23

15 &lt;160&gt; 12

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

20 &lt;211&gt; 412

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

25 &lt;223&gt; Description of Artificial Sequence:protein Q expressed in PQ31

&lt;400&gt; 1

Met Arg Gly Ser His His His His His His Thr Asp Pro His Ala Ser  
1 5 10 15

30 Ser Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Asn Leu Gly Ile Glu Gly  
20 25 30

35 Arg Pro Leu Ala Thr Pro Arg Ser Ala Lys Lys Ala Val Arg Lys Ser  
35 40 45

Gly Ser Lys Ser Ala Lys Cys Gly Leu Ile Phe Pro Val Gly Arg Val  
50 55 60

40 Gly Gly Met Met Arg Arg Gly Gln Tyr Ala Arg Arg Ile Gly Ala Ser  
65 70 75 80

Gly Ala Pro Arg Ile Ser Glu Phe Ser Val Lys Ala Ala Ala Gln Ser  
85 90 95

45 Gly Lys Lys Arg Cys Arg Leu Asn Pro Arg Thr Val Met Leu Ala Ala  
100 105 110

50 Arg His Asp Asp Asp Ile Gly Thr Leu Leu Lys Asn Val Thr Leu Ser  
115 120 125

His Ser Gly Val Val Pro Asn Ile Ser Lys Ala Met Ala Lys Lys Lys  
130 135 140

55 Gly Gly Lys Lys Gly Lys Ala Thr Pro Ser Ala Pro Glu Phe Gly Ser  
145 150 155 160

Ser Arg Pro Met Ser Thr Lys Tyr Leu Ala Ala Tyr Ala Leu Ala Ser  
165 170 175

60 Leu Ser Lys Ala Ser Pro Ser Gln Ala Asp Val Glu Ala Ile Cys Lys  
180 185 190

65 Ala Val His Ile Asp Val Asp Gln Ala Thr Leu Ala Phe Val Met Glu  
195 200 205

- 2 -

Ser Val Thr Gly Arg Asp Val Ala Thr Leu Ile Ala Glu Gly Ala Ala  
 210 215 220  
 5 Lys Met Ser Ala Met Pro Ala Ala Ser Ser Gly Ala Ala Ala Gly Val  
 225 230 235 240  
 Thr Ala Ser Ala Ala Gly Asp Ala Ala Pro Ala Ala Ala Ala Ala Lys  
 245 250 255  
 10 Lys Asp Glu Pro Glu Glu Glu Ala Asp Asp Asp Met Gly Pro Ser Arg  
 260 265 270  
 Val Asp Pro Met Gln Tyr Leu Ala Ala Tyr Ala Leu Val Ala Leu Ser  
 275 280 285  
 15 Gly Lys Thr Pro Ser Lys Ala Asp Val Gln Ala Val Leu Lys Ala Ala  
 290 295 300  
 20 Gly Val Ala Val Asp Ala Ser Arg Val Asp Ala Val Phe Gln Glu Val  
 305 310 315 320  
 Glu Gly Lys Ser Phe Asp Ala Leu Val Ala Glu Gly Arg Thr Lys Leu  
 325 330 335  
 25 Val Gly Ser Gly Ser Ala Ala Pro Ala Gly Ala Val Ser Thr Ala Gly  
 340 345 350  
 30 Ala Gly Ala Gly Ala Val Ala Glu Ala Lys Lys Glu Glu Pro Glu Glu  
 355 360 365  
 Glu Glu Ala Asp Asp Asp Met Gly Pro Val Asp Leu Gln Pro Ala Ala  
 370 375 380  
 35 Ala Ala Pro Ala Ala Pro Ser Ala Ala Ala Lys Glu Glu Pro Glu Glu  
 385 390 395 400  
 Ser Asp Glu Asp Asp Phe Gly Met Gly Gly Leu Phe  
 405 410  
 40  
 <210> 2  
 <211> 1436  
 45 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: DNA encoding  
 50 protein Q  
 <400> 2  
 atgagaggat ctcaccacca ccaccaccac acggatccgc atgcgagctc gaacaacaac 60  
 55 aacaataaca ataacaacaa cctcgggatc gaggaaggc ctttagctac tcctcgcagc  
 120 gccaaagaagg ccgtccgcaa gagcggctcc aagtccgcga aatgtggtct gatcttccc  
 180 gtgggccgcg tcggcgggat gatgcgccgc ggccagtaag ctgcgccgat cgggtgcctct  
 240 ggcgccccca ggatttcaga attctccgtg aaggcggccg cgcagagcgg gaagaagcgg  
 300 tgccgcctga acccgcgcac cgtgatgctg gccgcgcgcc acgacgacga catcgggcag  
 360

- 3 -

cttctgaaga acgtgacctt gtctcacagc ggcgttgtgc cgaacatcag caaggcgatg  
 420  
 gcaaagaaga agggcgga gaaaggcaag gcgacaccga gcgcgcccga attcgatcc  
 480  
 5 tctagacca tgtccacca gtacctcgcc gcgtacgctc tggcctccct gagcaaggcg  
 540  
 tccccgtctc aggcggacgt ggaggctatc tgcaaggccg tccacatcga cgtcgaccag  
 600  
 gccaccctcg cttttgtgat ggagagcgtt acgggacgcg acgtggccac cctgatcgcg  
 660  
 10 gagggcgccg cgaagatgag cgcgatgccg gcggccagct ctggtgccgc tgctggcgctc  
 720  
 actgcttccg ctgcgggtga tgcggctccg gctgccgcgc ccgcgaagaa ggacgagccc  
 780  
 15 gaggaggagg ccgacgacga catgggcccc tctagagtcg accccatgca gtacctcgcc  
 840  
 gcgtacgcc tctggcgct gtctggcaag acgccgtcga aggcggacgt tcaggctgtc  
 900  
 ctgaaggccg ccggcggtgc cgtggatgcc tcccgcgtgg atgccgtctt ccaggaggtg  
 960  
 20 gagggcaaga gcttcgatgc gctggtggcc gagggccgca cgaagctggt gggctctggc  
 1020  
 tctgccgctc ctgctggcgc tgtctccact gctggtgccg gcgctggcgc ggtggccgag  
 1080  
 25 gcgaagaagg aggagcccga ggaggaggag gccgatgatg acatgggccc cgtcgacctg  
 1140  
 cagcccgcgc ctgccgcgc gcccgcccct agcgcgcgtg ccaaggagga gccggaggag  
 1200  
 agcgacgagg acgacttcgg catgggcggt ctcttctaag cgactcgcca tctcttagcc  
 1260  
 30 tccttgtggt gcgcttgagg tgctctcgct ctgcttctcc ttgcagtgtt ggctgactct  
 1320  
 ggcggttatg tgccgtcgca ttacaccac ctctcccacc cttttgccct acgcgctcgc  
 1380  
 35 atgcgcaatc cgtgaatcat cgagggaagt ctctctgggt ggcagtgggt aagctt  
 1436

<210> 3  
 <211> 328  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 45 <223> Description of Artificial Sequence:protein Q expressed in pMal

<400> 3  
 Ile Glu Gly Arg Pro Leu Thr Pro Arg Ser Ala Lys Lys Ala Val Arg  
 1 5 10 15  
 50 Lys Ser Gly Ser Lys Ser Ala Lys Cys Gly Leu Ile Phe Pro Val Gly  
 20 25 30  
 55 Arg Val Gly Gly Met Met Arg Arg Gly Tyr Ala Arg Arg Ile Gly Ala  
 35 40 45  
 Ser Gly Ala Pro Arg Ile Ser Glu Phe Ser Val Lys Ala Ala Ala Gln  
 50 55 60  
 60 Ser Gly Lys Lys Arg Cys Arg Leu Asn Pro Arg Thr Val Met Leu Ala  
 65 70 75 80  
 Ala Arg His Asp Asp Asp Ile Gly Thr Leu Leu Lys Asn Val Thr Leu  
 85 90 95  
 65

- 4 -

Ser His Ser Gly Val Val Pro Asn Ile Ser Lys Ala Met Ala Lys Lys  
 100 105 110  
 5 Lys Gly Gly Lys Lys Gly Lys Ala Thr Pro Ser Ala Pro Glu Phe Gly  
 115 120 125  
 Asp Ser Ser Arg Pro Met Ser Thr Lys Tyr Leu Ala Ala Tyr Ala Leu  
 130 135 140  
 10 Ala Ser Leu Ser Lys Ala Ser Pro Ser Gln Ala Asp Val Glu Ala Ile  
 145 150 155 160  
 Cys Lys Ala Val His Ile Asp Val Asp Gln Ala Thr Leu Ala Phe Val  
 165 170 175  
 15 Met Glu Ser Val Thr Gly Arg Asp Val Ala Thr Leu Ile Ala Glu Gly  
 180 185 190  
 20 Ala Ala Lys Met Ser Ala Met Pro Ala Ala Ser Ser Gly Ala Ala Ala  
 195 200 205  
 Gly Val Thr Ala Ser Ala Ala Gly Asp Ala Ala Pro Ala Ala Ala  
 210 215 220  
 25 Ala Lys Lys Asp Glu Pro Glu Glu Glu Ala Asp Asp Asp Met Gly Pro  
 225 230 235 240  
 Ser Val Arg Asp Pro Met Gln Tyr Leu Ala Ala Tyr Ala Leu Val Ala  
 245 250 255  
 30 Leu Ser Gly Lys Thr Pro Ser Lys Ser Thr Ala Gly Ala Gly Ala Gly  
 260 265 270  
 35 Ala Val Ala Glu Ala Lys Lys Glu Glu Pro Glu Glu Glu Glu Ala Asp  
 275 280 285  
 Asp Asp Met Gly Pro Val Asp Leu Gln Pro Ala Ala Ala Ala Pro Ala  
 290 295 300  
 40 Ala Pro Ser Ala Ala Ala Lys Ala Ala Pro Glu Glu Ser Asp Glu Asp  
 305 310 315 320  
 Asp Phe Gly Met Gly Gly Leu Phe  
 325

45

50 <210> 4  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

55 <220>  
 <223> Description of Artificial Sequence:oligonucleotide

<400> 4  
 ccttttagcta ctctcgcag cgccaag

27

60

<210> 5  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

65



- 5 -

<220>  
<223> Description of Artificial Sequence:oligonucleotide  
  
<400> 5  
5 cctgggggcg ccagaggcac cgatgcg 27  
  
<210> 6  
10 <211> 26  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
15 <223> Description of Artificial Sequence:oligonucleotide  
  
<400> 6  
gaattctccg taaggcggcc ggcgag 26  
20  
  
<210> 7  
<211> 30  
<212> DNA  
25 <213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:oligonucleotide  
30 <400> 7  
gaattcgggc gcgctcggtg tcgccttgcc 30  
  
<210> 8  
35 <211> 30  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
40 <223> Description of Artificial Sequence:oligonucleotide  
  
<400> 8  
45 gtcgacccca tgcagtacct cgccgcgtac 30  
  
<210> 9  
50 <211> 30  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
55 <223> Description of Artificial Sequence:oligonucleotide  
  
<400> 9  
gtcgacgggg cccatgtcat catcggcctc 30  
  
<210> 10  
60 <211> 32  
<212> DNA  
65 <213> Artificial Sequence

- 6 -

<220>  
<223> Description of Artificial Sequence:oligonucleotide

5      <400> 10  
tctagaccgc ccatgtcgtc gtcttcctcg cc 32

10      <210> 11  
         <211> 29  
         <212> DNA  
         <213> Artificial Sequence

15      <220>  
         <223> Description of Artificial Sequence:oligonucleotide

         <400> 11  
tctagagggg ccatgtcgtc gtcggcctc 29

20

         <210> 12  
         <211> 30  
         <212> DNA  
25      <213> Artificial Sequence

         <220>  
         <223> Description of Artificial Sequence:oligonucleotide

30      <400> 12  
ctgcagccgc ccgctgccgc gccggccgcc 30

35

## INTERNATIONAL SEARCH REPORT

Inte Jonal Application No

PCT/EP 99/10441

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/30 C12N15/62 C07K14/44 C07K16/20 A61K31/70  
 A61K38/16 A61K39/395 A61P33/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SOTO M. ET AL.: "Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis" J. CLINICAL MICROBIOLOGY, vol. 36, no. 1, January 1998 (1998-01), pages 58-63, XP002137284 the whole document	1-11
P, X, L	ES 2 133 236 A (LETI LAB) 1 September 1999 (1999-09-01) the whole document L: older priority	1-11
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 May 2000

Date of mailing of the international search report

22/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Galli, I

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/10441

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RICO A.I. ET AL.: "Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the E. coli Maltose-Binding Protein in normal and nu/nu mice." INF. IMMUN., vol. 66, no. 1, January 1998 (1998-01), pages 347-352, XP002137285 the whole document	1-11
A	WO 96 33414 A (CORIXA CORP) 24 October 1996 (1996-10-24) abstract	1-11
A	WO 96 10081 A (PASTEUR INSTITUT ;INST PASTEUR DE TUNIS (TN); GICQUEL BRIGITTE (FR) 4 April 1996 (1996-04-04) abstract	1-11

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/10441

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark: Although claims 10-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/10441

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
ES 2133236	A	01-09-1999	NONE		
WO 9633414	A	24-10-1996	US	5912166 A	15-06-1999
			AU	5559496 A	07-11-1996
			BR	9608016 A	02-03-1999
			EP	0824699 A	25-02-1998
WO 9610081	A	04-04-1996	EP	0703295 A	27-03-1996
			AU	3742395 A	19-04-1996